[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fdFOWt42nZ8TqFZkJYSyxJvgj5n8ab55IWgZvGkPRXe0":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":8,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":34,"phaseBuckets":35,"rows":42},"National Center for Research Resources (NCRR)",[4],265,false,0,30,19150,111,[13,16,19,22,24,26,29,31],{"name":14,"count":15},"Cystic Fibrosis",13,{"name":17,"count":18},"Systemic Lupus Erythematosus",8,{"name":20,"count":21},"HIV Infections",7,{"name":23,"count":21},"Porphyria",{"name":25,"count":21},"Diabetes Mellitus",{"name":27,"count":28},"Tourette Syndrome",5,{"name":30,"count":28},"Osteoporosis",{"name":32,"count":33},"Multiple Sclerosis",4,[],[36,37,38,39,40,41],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[43,68,90,112,136,183,230,274,308,342,372,400,430,453,479,503,521,539,557,583,606,629,653,675,696,720,738,761,786,811,829,847,865,888,911,958,988,1029,1053,1077,1101,1123,1148,1174,1196,1218,1240,1263,1287,1309,1327,1351,1376,1394,1412,1434,1460,1478,1496,1514,1536,1558,1582,1600,1623,1647,1670,1692,1714,1735,1761,1779,1797,1815,1833,1856,1881,1903,1926,1944,1966,1988,2013,2031,2053,2078,2102,2128,2146,2170,2188,2206,2230,2253,2275,2297,2315,2337,2359,2381,2402,2423,2444,2466,2488,2510,2531,2553,2576,2594,2616,2638,2660,2694,2729,2771,2803,2834,2873,2899,2927,2949,2977,3008,3034,3060,3090,3131,3153,3175,3201,3223,3246,3271,3289,3312,3335,3353,3375,3396,3417,3435,3456,3478,3501,3519,3541,3559,3582,3604,3627,3650,3672,3695,3719,3737,3760,3778,3796,3814,3832,3850,3868,3886,3904,3926,3949,3971,3989,4018,4036,4060,4078,4096,4121,4139,4157,4175,4200],{"intervention":44,"totalTrials":45,"cells":46},"epoprostenol",1,{"EARLY_PHASE1":47,"PHASE1":49,"PHASE2":51,"PHASE3":53,"PHASE4":55,"NA":66},{"trials":48,"activeCount":8},[],{"trials":50,"activeCount":8},[],{"trials":52,"activeCount":8},[],{"trials":54,"activeCount":8},[],{"trials":56,"activeCount":8},[57],{"nctId":58,"briefTitle":59,"status":60,"phases":61,"start":62,"conditions":63,"interventions":65},"NCT00004754","Phase IV Study of Chronic Infusional Epoprostenol for Severe Primary Pulmonary Hypertension","COMPLETED",[40],"1993-08",[64],"Hypertension, Pulmonary",[44],{"trials":67,"activeCount":8},[],{"intervention":69,"totalTrials":45,"cells":70},"methylphenidate",{"EARLY_PHASE1":71,"PHASE1":73,"PHASE2":75,"PHASE3":77,"PHASE4":79,"NA":88},{"trials":72,"activeCount":8},[],{"trials":74,"activeCount":8},[],{"trials":76,"activeCount":8},[],{"trials":78,"activeCount":8},[],{"trials":80,"activeCount":8},[81],{"nctId":82,"briefTitle":83,"status":60,"phases":84,"conditions":85,"interventions":87},"NCT00035139","Pediatric Traumatic Brain Injury: Methylphenidate Effects on Early Recovery",[40],[86],"Brain Injuries",[69],{"trials":89,"activeCount":8},[],{"intervention":91,"totalTrials":45,"cells":92},"Vitamin E",{"EARLY_PHASE1":93,"PHASE1":95,"PHASE2":97,"PHASE3":99,"PHASE4":101,"NA":110},{"trials":94,"activeCount":8},[],{"trials":96,"activeCount":8},[],{"trials":98,"activeCount":8},[],{"trials":100,"activeCount":8},[],{"trials":102,"activeCount":8},[103],{"nctId":104,"briefTitle":105,"status":60,"phases":106,"conditions":107,"interventions":109},"NCT00004637","Double-Blind, Placebo-Controlled Trial of Vitamin E as Add-on Therapy for Children With Epilepsy",[40],[108],"Epilepsy",[91],{"trials":111,"activeCount":8},[],{"intervention":113,"totalTrials":45,"cells":114},"zinc acetate",{"EARLY_PHASE1":115,"PHASE1":117,"PHASE2":119,"PHASE3":121,"PHASE4":123,"NA":134},{"trials":116,"activeCount":8},[],{"trials":118,"activeCount":8},[],{"trials":120,"activeCount":8},[],{"trials":122,"activeCount":8},[],{"trials":124,"activeCount":8},[125],{"nctId":126,"briefTitle":127,"status":60,"phases":128,"start":129,"enrollment":130,"conditions":131,"interventions":133},"NCT00004338","Study of Zinc for Wilson Disease",[40],"1993-10",300,[132],"Wilson Disease",[113],{"trials":135,"activeCount":8},[],{"intervention":137,"totalTrials":33,"cells":138},"acyclovir",{"EARLY_PHASE1":139,"PHASE1":141,"PHASE2":143,"PHASE3":154,"PHASE4":179,"NA":181},{"trials":140,"activeCount":8},[],{"trials":142,"activeCount":8},[],{"trials":144,"activeCount":8},[145],{"nctId":146,"briefTitle":147,"status":60,"phases":148,"start":149,"enrollment":150,"conditions":151,"interventions":153},"NCT00004644","Phase I\u002FII Study of High-Dose Acyclovir for Central Nervous System or Disseminated Neonatal Herpes Simplex Virus Infection",[37,38],"1995-02",25,[152],"Herpes Simplex",[137],{"trials":155,"activeCount":8},[156,164,172],{"nctId":157,"briefTitle":158,"status":60,"phases":159,"start":160,"enrollment":161,"conditions":162,"interventions":163},"NCT00006135","Phase III Randomized Study of Oral Acyclovir in Infants With Herpes Simplex Virus Infection Limited to Skin, Eyes, and Mouth",[39],"1997-06",66,[152],[137],{"nctId":165,"briefTitle":166,"status":167,"phases":168,"start":160,"enrollment":169,"conditions":170,"interventions":171},"NCT00006132","Phase III Randomized Study of Oral Acyclovir in Infants With Herpes Simplex Virus Infection Involving the Central Nervous System","UNKNOWN",[39],132,[152],[137],{"nctId":173,"briefTitle":174,"status":60,"phases":175,"start":176,"conditions":177,"interventions":178},"NCT00004757","Phase III Randomized, Placebo-Controlled Study of Acyclovir Oral Suspension for Neonatal Herpes Simplex Virus Infection Limited to the Skin, Eyes, and Mouth",[39],"1992-08",[152],[137],{"trials":180,"activeCount":8},[],{"trials":182,"activeCount":8},[],{"intervention":184,"totalTrials":33,"cells":185},"dehydroepiandrosterone",{"EARLY_PHASE1":186,"PHASE1":188,"PHASE2":190,"PHASE3":200,"PHASE4":226,"NA":228},{"trials":187,"activeCount":8},[],{"trials":189,"activeCount":8},[],{"trials":191,"activeCount":8},[192],{"nctId":193,"briefTitle":194,"status":60,"phases":195,"start":196,"enrollment":197,"conditions":198,"interventions":199},"NCT00004665","Phase II Study of Long-Term Dehydroepiandrosterone for Systemic Lupus Erythematosus",[38],"1995-06",20,[17],[184],{"trials":201,"activeCount":8},[202,211,219],{"nctId":203,"briefTitle":204,"status":60,"phases":205,"start":206,"enrollment":207,"conditions":208,"interventions":210},"NCT00004313","Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone Replacement for Primary Adrenal Insufficiency",[39],"1995-08",40,[209],"Addison's Disease",[184],{"nctId":212,"briefTitle":213,"status":60,"phases":214,"start":215,"enrollment":216,"conditions":217,"interventions":218},"NCT00004795","Phase II\u002FIII Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone in Women With Mild to Moderate Systemic Lupus Erythematosus",[38,39],"1994-08",190,[17],[184],{"nctId":220,"briefTitle":221,"status":60,"phases":222,"start":223,"enrollment":130,"conditions":224,"interventions":225},"NCT00004662","Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone in Women With Active Systemic Lupus Erythematosus",[39],"1996-03",[17],[184],{"trials":227,"activeCount":8},[],{"trials":229,"activeCount":8},[],{"intervention":231,"totalTrials":232,"cells":233},"ursodiol",3,{"EARLY_PHASE1":234,"PHASE1":236,"PHASE2":238,"PHASE3":249,"PHASE4":270,"NA":272},{"trials":235,"activeCount":8},[],{"trials":237,"activeCount":8},[],{"trials":239,"activeCount":8},[240],{"nctId":241,"briefTitle":242,"status":167,"phases":243,"start":244,"enrollment":197,"conditions":245,"interventions":248},"NCT00004315","Phase II Pilot Study to Compare the Bioavailability of Buffered, Enteric-Coated Ursodiol With Unmodified Ursodiol for Chronic Cholestatic Liver Disease and Cystic Fibrosis-Associated Liver Disease",[38],"1995-11",[14,246,247],"Gastrointestinal Diseases","Cholestasis",[231],{"trials":250,"activeCount":8},[251,262],{"nctId":252,"briefTitle":253,"status":60,"phases":254,"start":255,"enrollment":256,"conditions":257,"interventions":259},"NCT00004748","Low-Dose Oral Methotrexate Versus Colchicine for Primary Biliary Cirrhosis",[39],"1989-11",90,[258],"Liver Cirrhosis, Biliary",[260,261,231],"colchicine","methotrexate",{"nctId":263,"briefTitle":264,"status":60,"phases":265,"start":266,"enrollment":267,"conditions":268,"interventions":269},"NCT00004784","Phase III Randomized Study of Ursodiol With Vs Without Methotrexate for Primary Biliary Cirrhosis",[39],"1994-01",315,[258],[261,231],{"trials":271,"activeCount":8},[],{"trials":273,"activeCount":8},[],{"intervention":275,"totalTrials":276,"cells":277},"immune globulin",2,{"EARLY_PHASE1":278,"PHASE1":280,"PHASE2":282,"PHASE3":284,"PHASE4":304,"NA":306},{"trials":279,"activeCount":8},[],{"trials":281,"activeCount":8},[],{"trials":283,"activeCount":8},[],{"trials":285,"activeCount":8},[286,296],{"nctId":287,"briefTitle":288,"status":60,"phases":289,"completion":290,"start":291,"enrollment":292,"conditions":293,"interventions":295},"NCT00004286","Phase III Multicenter Double Blind Controlled Trial of Human Immune Globulin Therapy in Previously Untreated Patients With Chronic Inflammatory Demyelinating Neuropathy",[39],"1999-11","1996-02",120,[294],"Polyradiculoneuropathy, Chronic Inflammatory Demyelinating",[275],{"nctId":297,"briefTitle":298,"status":60,"phases":299,"start":300,"enrollment":256,"conditions":301,"interventions":302},"NCT00004772","Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating Polyneuropathy",[39],"1992-09",[294],[303],"Immune globulin",{"trials":305,"activeCount":8},[],{"trials":307,"activeCount":8},[],{"intervention":309,"totalTrials":276,"cells":310},"dexamethasone",{"EARLY_PHASE1":311,"PHASE1":313,"PHASE2":315,"PHASE3":317,"PHASE4":338,"NA":340},{"trials":312,"activeCount":8},[],{"trials":314,"activeCount":8},[],{"trials":316,"activeCount":8},[],{"trials":318,"activeCount":8},[319,329],{"nctId":320,"briefTitle":321,"status":60,"phases":322,"start":62,"enrollment":323,"conditions":324,"interventions":326},"NCT00004778","Phase III Randomized, Double-Blind, Placebo-Controlled Study of Antenatal Thyrotropin-Releasing Hormone in Pregnant Women With Threatened Premature Delivery",[39],1090,[325],"Respiratory Distress Syndrome",[327,309,328],"betamethasone","thyrotropin-releasing hormone",{"nctId":330,"briefTitle":331,"status":60,"phases":332,"start":244,"enrollment":333,"conditions":334,"interventions":336},"NCT00004785","Phase III Randomized, Double-Blind Study of Dexamethasone Vs Dexamethasone\u002FMethylprednisolone Vs Placebo for Bronchopulmonary Dysplasia",[39],54,[335],"Bronchopulmonary Dysplasia",[309,337],"methylprednisolone",{"trials":339,"activeCount":8},[],{"trials":341,"activeCount":8},[],{"intervention":337,"totalTrials":276,"cells":343},{"EARLY_PHASE1":344,"PHASE1":346,"PHASE2":348,"PHASE3":362,"PHASE4":368,"NA":370},{"trials":345,"activeCount":8},[],{"trials":347,"activeCount":8},[],{"trials":349,"activeCount":8},[350],{"nctId":351,"briefTitle":352,"status":60,"phases":353,"start":149,"enrollment":354,"conditions":355,"interventions":357},"NCT00004323","Phase II Study of Bone Marrow Transplantation Using Related Donors in Patients With Aplastic Anemia",[38],10,[356],"Aplastic Anemia",[358,359,360,361,261,337],"anti-thymocyte globulin","cyclophosphamide","cyclosporine","mesna",{"trials":363,"activeCount":8},[364],{"nctId":330,"briefTitle":331,"status":60,"phases":365,"start":244,"enrollment":333,"conditions":366,"interventions":367},[39],[335],[309,337],{"trials":369,"activeCount":8},[],{"trials":371,"activeCount":8},[],{"intervention":260,"totalTrials":276,"cells":373},{"EARLY_PHASE1":374,"PHASE1":376,"PHASE2":388,"PHASE3":390,"PHASE4":396,"NA":398},{"trials":375,"activeCount":8},[],{"trials":377,"activeCount":8},[378],{"nctId":379,"briefTitle":380,"status":167,"phases":381,"start":382,"enrollment":383,"conditions":384,"interventions":387},"NCT00004368","Phase I Study of Colchicine Therapy in Childhood Hepatic Cirrhosis",[37],"1990-05",15,[385,386],"Cirrhosis","Liver Cirrhosis",[260],{"trials":389,"activeCount":8},[],{"trials":391,"activeCount":8},[392],{"nctId":252,"briefTitle":253,"status":60,"phases":393,"start":255,"enrollment":256,"conditions":394,"interventions":395},[39],[258],[260,261,231],{"trials":397,"activeCount":8},[],{"trials":399,"activeCount":8},[],{"intervention":401,"totalTrials":276,"cells":402},"tetrathiomolybdate",{"EARLY_PHASE1":403,"PHASE1":405,"PHASE2":407,"PHASE3":417,"PHASE4":426,"NA":428},{"trials":404,"activeCount":8},[],{"trials":406,"activeCount":8},[],{"trials":408,"activeCount":8},[409],{"nctId":410,"briefTitle":411,"status":60,"phases":412,"conditions":413,"interventions":415},"NCT00006332","Treatment of Hepatocellular Carcinoma With Tetrathiomolybdate",[38],[414],"Carcinoma, Hepatocellular",[416],"Tetrathiomolybdate",{"trials":418,"activeCount":8},[419],{"nctId":420,"briefTitle":421,"status":60,"phases":422,"start":266,"enrollment":256,"conditions":423,"interventions":424},"NCT00004339","Study of Tetrathiomolybdate in Patients With Wilson Disease",[39],[132],[401,425],"trientine",{"trials":427,"activeCount":8},[],{"trials":429,"activeCount":8},[],{"intervention":431,"totalTrials":45,"cells":432},"prednisone",{"EARLY_PHASE1":433,"PHASE1":435,"PHASE2":437,"PHASE3":439,"PHASE4":449,"NA":451},{"trials":434,"activeCount":8},[],{"trials":436,"activeCount":8},[],{"trials":438,"activeCount":8},[],{"trials":440,"activeCount":8},[441],{"nctId":442,"briefTitle":443,"status":60,"phases":444,"start":445,"enrollment":197,"conditions":446,"interventions":448},"NCT00004646","Phase III Randomized, Double-Blind Study of Prednisone for Duchenne Muscular Dystrophy",[39],"1995-04",[447],"Duchenne Muscular Dystrophy",[431],{"trials":450,"activeCount":8},[],{"trials":452,"activeCount":8},[],{"intervention":454,"totalTrials":45,"cells":455},"dichlorphenamide",{"EARLY_PHASE1":456,"PHASE1":458,"PHASE2":460,"PHASE3":462,"PHASE4":475,"NA":477},{"trials":457,"activeCount":8},[],{"trials":459,"activeCount":8},[],{"trials":461,"activeCount":8},[],{"trials":463,"activeCount":8},[464],{"nctId":465,"briefTitle":466,"status":60,"phases":467,"start":468,"enrollment":469,"conditions":470,"interventions":474},"NCT00004802","Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dichlorphenamide for Periodic Paralyses and Associated Sodium Channel Disorders",[39],"1992-06",64,[471,472,473],"Paralysis, Hyperkalemic Periodic","Hypokalemic Periodic Paralysis","Paramyotonia Congenita",[454],{"trials":476,"activeCount":8},[],{"trials":478,"activeCount":8},[],{"intervention":480,"totalTrials":45,"cells":481},"potassium citrate",{"EARLY_PHASE1":482,"PHASE1":484,"PHASE2":486,"PHASE3":488,"PHASE4":499,"NA":501},{"trials":483,"activeCount":8},[],{"trials":485,"activeCount":8},[],{"trials":487,"activeCount":8},[],{"trials":489,"activeCount":8},[490],{"nctId":491,"briefTitle":492,"status":60,"phases":493,"start":445,"enrollment":130,"conditions":494,"interventions":497},"NCT00004284","Phase III Randomized, Double-Blind Study of Potassium Phosphate Vs Potassium Citrate for Absorptive Hypercalciuria",[39],[495,496],"Hypercalciuria","Kidney Calculi",[480,498],"potassium phosphate",{"trials":500,"activeCount":8},[],{"trials":502,"activeCount":8},[],{"intervention":498,"totalTrials":45,"cells":504},{"EARLY_PHASE1":505,"PHASE1":507,"PHASE2":509,"PHASE3":511,"PHASE4":517,"NA":519},{"trials":506,"activeCount":8},[],{"trials":508,"activeCount":8},[],{"trials":510,"activeCount":8},[],{"trials":512,"activeCount":8},[513],{"nctId":491,"briefTitle":492,"status":60,"phases":514,"start":445,"enrollment":130,"conditions":515,"interventions":516},[39],[495,496],[480,498],{"trials":518,"activeCount":8},[],{"trials":520,"activeCount":8},[],{"intervention":327,"totalTrials":45,"cells":522},{"EARLY_PHASE1":523,"PHASE1":525,"PHASE2":527,"PHASE3":529,"PHASE4":535,"NA":537},{"trials":524,"activeCount":8},[],{"trials":526,"activeCount":8},[],{"trials":528,"activeCount":8},[],{"trials":530,"activeCount":8},[531],{"nctId":320,"briefTitle":321,"status":60,"phases":532,"start":62,"enrollment":323,"conditions":533,"interventions":534},[39],[325],[327,309,328],{"trials":536,"activeCount":8},[],{"trials":538,"activeCount":8},[],{"intervention":328,"totalTrials":45,"cells":540},{"EARLY_PHASE1":541,"PHASE1":543,"PHASE2":545,"PHASE3":547,"PHASE4":553,"NA":555},{"trials":542,"activeCount":8},[],{"trials":544,"activeCount":8},[],{"trials":546,"activeCount":8},[],{"trials":548,"activeCount":8},[549],{"nctId":320,"briefTitle":321,"status":60,"phases":550,"start":62,"enrollment":323,"conditions":551,"interventions":552},[39],[325],[327,309,328],{"trials":554,"activeCount":8},[],{"trials":556,"activeCount":8},[],{"intervention":558,"totalTrials":45,"cells":559},"mexiletine",{"EARLY_PHASE1":560,"PHASE1":562,"PHASE2":564,"PHASE3":566,"PHASE4":579,"NA":581},{"trials":561,"activeCount":8},[],{"trials":563,"activeCount":8},[],{"trials":565,"activeCount":8},[],{"trials":567,"activeCount":8},[568],{"nctId":569,"briefTitle":570,"status":60,"phases":571,"completion":572,"start":573,"enrollment":207,"conditions":574,"interventions":578},"NCT00004647","Phase III Randomized, Double-Blind, Placebo-Controlled Study of Mexiletine for Painful Diabetic Neuropathy",[39],"1999-02","1993-03",[575,576,577],"Pain","Diabetic Neuropathies","Paresthesia",[558],{"trials":580,"activeCount":8},[],{"trials":582,"activeCount":8},[],{"intervention":584,"totalTrials":45,"cells":585},",4-diaminopyridine",{"EARLY_PHASE1":586,"PHASE1":588,"PHASE2":590,"PHASE3":592,"PHASE4":602,"NA":604},{"trials":587,"activeCount":8},[],{"trials":589,"activeCount":8},[],{"trials":591,"activeCount":8},[],{"trials":593,"activeCount":8},[594],{"nctId":595,"briefTitle":596,"status":60,"phases":597,"completion":598,"start":598,"enrollment":599,"conditions":600,"interventions":601},"NCT00004939","Phase III Randomized, Double-Blind, Placebo-Controlled Study of 3,4-Diaminopyridine for Demyelinating Polyneuropathy",[39],"1996-08",34,[294],[584],{"trials":603,"activeCount":8},[],{"trials":605,"activeCount":8},[],{"intervention":607,"totalTrials":45,"cells":608},"copolymer 1",{"EARLY_PHASE1":609,"PHASE1":611,"PHASE2":613,"PHASE3":615,"PHASE4":625,"NA":627},{"trials":610,"activeCount":8},[],{"trials":612,"activeCount":8},[],{"trials":614,"activeCount":8},[],{"trials":616,"activeCount":8},[617],{"nctId":618,"briefTitle":619,"status":60,"phases":620,"start":621,"enrollment":622,"conditions":623,"interventions":624},"NCT00004814","Phase III Randomized, Double-Blind, Placebo-Controlled Study of Copolymer 1 for Relapsing-Remitting Multiple Sclerosis",[39],"1991-10",250,[32],[607],{"trials":626,"activeCount":8},[],{"trials":628,"activeCount":8},[],{"intervention":630,"totalTrials":45,"cells":631},"soy protein isolate",{"EARLY_PHASE1":632,"PHASE1":634,"PHASE2":636,"PHASE3":638,"PHASE4":649,"NA":651},{"trials":633,"activeCount":8},[],{"trials":635,"activeCount":8},[],{"trials":637,"activeCount":8},[],{"trials":639,"activeCount":8},[640],{"nctId":641,"briefTitle":642,"status":60,"phases":643,"start":644,"enrollment":645,"conditions":646,"interventions":648},"NCT00004654","Phase III Randomized, Placebo-Controlled, Crossover Study of Soy Protein Isolate for Hereditary Hemorrhagic Telangiectasia",[39],"1996-01",60,[647],"Hereditary Hemorrhagic Telangiectasia",[630],{"trials":650,"activeCount":8},[],{"trials":652,"activeCount":8},[],{"intervention":654,"totalTrials":45,"cells":655},"tumor-pulsed dendritic cells",{"EARLY_PHASE1":656,"PHASE1":658,"PHASE2":660,"PHASE3":662,"PHASE4":671,"NA":673},{"trials":657,"activeCount":8},[],{"trials":659,"activeCount":8},[],{"trials":661,"activeCount":8},[],{"trials":663,"activeCount":8},[664],{"nctId":665,"briefTitle":666,"status":60,"phases":667,"conditions":668,"interventions":670},"NCT00006434","Tumor Lysate Pulsed-Dendritic Cell Vaccines After High-Dose Chemotherapy for Non-Hodgkin's Lymphoma",[39],[669],"Lymphoma, Non-Hodgkin",[654],{"trials":672,"activeCount":8},[],{"trials":674,"activeCount":8},[],{"intervention":676,"totalTrials":45,"cells":677},"Human recombinant growth hormone",{"EARLY_PHASE1":678,"PHASE1":680,"PHASE2":682,"PHASE3":684,"PHASE4":692,"NA":694},{"trials":679,"activeCount":8},[],{"trials":681,"activeCount":8},[],{"trials":683,"activeCount":8},[],{"trials":685,"activeCount":8},[686],{"nctId":687,"briefTitle":688,"status":60,"phases":689,"conditions":690,"interventions":691},"NCT00005112","Growth Hormone Use in Cystic Fibrosis - a Multicenter Study",[39],[14],[676],{"trials":693,"activeCount":8},[],{"trials":695,"activeCount":8},[],{"intervention":697,"totalTrials":45,"cells":698},"guanfacine",{"EARLY_PHASE1":699,"PHASE1":701,"PHASE2":703,"PHASE3":705,"PHASE4":716,"NA":718},{"trials":700,"activeCount":8},[],{"trials":702,"activeCount":8},[],{"trials":704,"activeCount":8},[],{"trials":706,"activeCount":8},[707],{"nctId":708,"briefTitle":709,"status":60,"phases":710,"completion":711,"start":712,"enrollment":713,"conditions":714,"interventions":715},"NCT00004376","Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder",[39],"2000-06","1994-09",35,[27],[697],{"trials":717,"activeCount":8},[],{"trials":719,"activeCount":8},[],{"intervention":425,"totalTrials":45,"cells":721},{"EARLY_PHASE1":722,"PHASE1":724,"PHASE2":726,"PHASE3":728,"PHASE4":734,"NA":736},{"trials":723,"activeCount":8},[],{"trials":725,"activeCount":8},[],{"trials":727,"activeCount":8},[],{"trials":729,"activeCount":8},[730],{"nctId":420,"briefTitle":421,"status":60,"phases":731,"start":266,"enrollment":256,"conditions":732,"interventions":733},[39],[132],[401,425],{"trials":735,"activeCount":8},[],{"trials":737,"activeCount":8},[],{"intervention":739,"totalTrials":45,"cells":740},"topiramate",{"EARLY_PHASE1":741,"PHASE1":743,"PHASE2":745,"PHASE3":747,"PHASE4":757,"NA":759},{"trials":742,"activeCount":8},[],{"trials":744,"activeCount":8},[],{"trials":746,"activeCount":8},[],{"trials":748,"activeCount":8},[749],{"nctId":750,"briefTitle":751,"status":60,"phases":752,"start":753,"enrollment":354,"conditions":754,"interventions":756},"NCT00004776","Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Topiramate for Lennox-Gastaut Syndrome",[39],"1993-11",[755],"Lennox-Gastaut Syndrome",[739],{"trials":758,"activeCount":8},[],{"trials":760,"activeCount":8},[],{"intervention":762,"totalTrials":45,"cells":763},"iloprost",{"EARLY_PHASE1":764,"PHASE1":766,"PHASE2":768,"PHASE3":770,"PHASE4":782,"NA":784},{"trials":765,"activeCount":8},[],{"trials":767,"activeCount":8},[],{"trials":769,"activeCount":8},[],{"trials":771,"activeCount":8},[772],{"nctId":773,"briefTitle":774,"status":60,"phases":775,"start":776,"enrollment":777,"conditions":778,"interventions":781},"NCT00004786","Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis",[39],"1995-12",200,[779,780],"Systemic Sclerosis","Raynaud Disease",[762],{"trials":783,"activeCount":8},[],{"trials":785,"activeCount":8},[],{"intervention":787,"totalTrials":45,"cells":788},"desipramine",{"EARLY_PHASE1":789,"PHASE1":791,"PHASE2":793,"PHASE3":795,"PHASE4":807,"NA":809},{"trials":790,"activeCount":8},[],{"trials":792,"activeCount":8},[],{"trials":794,"activeCount":8},[],{"trials":796,"activeCount":8},[797],{"nctId":798,"briefTitle":799,"status":60,"phases":800,"start":149,"enrollment":292,"conditions":801,"interventions":803},"NCT00004390","Phase III Randomized Controlled Study of Morphine and Nortriptyline in the Management of Postherpetic Neuralgia",[39],[575,802],"Herpes Zoster",[787,804,805,806],"methadone","morphine","nortriptyline",{"trials":808,"activeCount":8},[],{"trials":810,"activeCount":8},[],{"intervention":804,"totalTrials":45,"cells":812},{"EARLY_PHASE1":813,"PHASE1":815,"PHASE2":817,"PHASE3":819,"PHASE4":825,"NA":827},{"trials":814,"activeCount":8},[],{"trials":816,"activeCount":8},[],{"trials":818,"activeCount":8},[],{"trials":820,"activeCount":8},[821],{"nctId":798,"briefTitle":799,"status":60,"phases":822,"start":149,"enrollment":292,"conditions":823,"interventions":824},[39],[575,802],[787,804,805,806],{"trials":826,"activeCount":8},[],{"trials":828,"activeCount":8},[],{"intervention":805,"totalTrials":45,"cells":830},{"EARLY_PHASE1":831,"PHASE1":833,"PHASE2":835,"PHASE3":837,"PHASE4":843,"NA":845},{"trials":832,"activeCount":8},[],{"trials":834,"activeCount":8},[],{"trials":836,"activeCount":8},[],{"trials":838,"activeCount":8},[839],{"nctId":798,"briefTitle":799,"status":60,"phases":840,"start":149,"enrollment":292,"conditions":841,"interventions":842},[39],[575,802],[787,804,805,806],{"trials":844,"activeCount":8},[],{"trials":846,"activeCount":8},[],{"intervention":806,"totalTrials":45,"cells":848},{"EARLY_PHASE1":849,"PHASE1":851,"PHASE2":853,"PHASE3":855,"PHASE4":861,"NA":863},{"trials":850,"activeCount":8},[],{"trials":852,"activeCount":8},[],{"trials":854,"activeCount":8},[],{"trials":856,"activeCount":8},[857],{"nctId":798,"briefTitle":799,"status":60,"phases":858,"start":149,"enrollment":292,"conditions":859,"interventions":860},[39],[575,802],[787,804,805,806],{"trials":862,"activeCount":8},[],{"trials":864,"activeCount":8},[],{"intervention":866,"totalTrials":45,"cells":867},"creatine monohydrate",{"EARLY_PHASE1":868,"PHASE1":870,"PHASE2":872,"PHASE3":874,"PHASE4":884,"NA":886},{"trials":869,"activeCount":8},[],{"trials":871,"activeCount":8},[],{"trials":873,"activeCount":8},[],{"trials":875,"activeCount":8},[876],{"nctId":877,"briefTitle":878,"status":60,"phases":879,"conditions":880,"interventions":882},"NCT00018109","A Multicenter Randomized Placebo-Controlled Double-Blind Study to Assess Efficacy and Safety of Glutamine and Creatine Monohydrate in Duchenne Muscular Dystrophy (DMD)",[39],[881],"Muscular Dystrophy, Duchenne",[883,866],"glutamine",{"trials":885,"activeCount":8},[],{"trials":887,"activeCount":8},[],{"intervention":889,"totalTrials":45,"cells":890},"interferon alfa",{"EARLY_PHASE1":891,"PHASE1":893,"PHASE2":895,"PHASE3":897,"PHASE4":907,"NA":909},{"trials":892,"activeCount":8},[],{"trials":894,"activeCount":8},[],{"trials":896,"activeCount":8},[],{"trials":898,"activeCount":8},[899],{"nctId":900,"briefTitle":901,"status":60,"phases":902,"start":62,"enrollment":903,"conditions":904,"interventions":906},"NCT00004804","Phase III Randomized Study of High Vs Standard Dose of Interferon Alfa for Chronic Hepatitis C",[39],57,[905],"Hepatitis C",[889],{"trials":908,"activeCount":8},[],{"trials":910,"activeCount":8},[],{"intervention":912,"totalTrials":33,"cells":913},"heme arginate",{"EARLY_PHASE1":914,"PHASE1":916,"PHASE2":934,"PHASE3":952,"PHASE4":954,"NA":956},{"trials":915,"activeCount":8},[],{"trials":917,"activeCount":8},[918,928],{"nctId":919,"briefTitle":920,"status":60,"phases":921,"completion":922,"start":923,"enrollment":924,"conditions":925,"interventions":926},"NCT00004398","Phase I Study of Heme Arginate With or Without Tin Mesoporphyrin in Patients With Acute Attacks of Porphyria",[37],"2000-05","1998-01",24,[23],[912,927],"tin mesoporphyrin",{"nctId":929,"briefTitle":930,"status":60,"phases":931,"completion":922,"start":923,"enrollment":197,"conditions":932,"interventions":933},"NCT00004397","Phase I Study of Tin Mesoporphyrin in Patients on Long Term Heme Therapy for Prevention of Acute Attacks of Porphyria",[37],[23],[912,927],{"trials":935,"activeCount":8},[936,944],{"nctId":937,"briefTitle":938,"status":60,"phases":939,"start":940,"enrollment":941,"conditions":942,"interventions":943},"NCT00004396","Studies in Porphyria III: Heme and Tin Mesoporphyrin in Acute Porphyrias",[38],"1997-09",32,[23],[912,927],{"nctId":945,"briefTitle":946,"status":60,"phases":947,"start":948,"enrollment":949,"conditions":950,"interventions":951},"NCT00004789","Phase I\u002FII Study of Heme Arginate and Tin Mesoporphyrin for Acute Porphyria",[37,38],"1993-07",59,[23],[912,927],{"trials":953,"activeCount":8},[],{"trials":955,"activeCount":8},[],{"trials":957,"activeCount":8},[],{"intervention":927,"totalTrials":33,"cells":959},{"EARLY_PHASE1":960,"PHASE1":962,"PHASE2":972,"PHASE3":982,"PHASE4":984,"NA":986},{"trials":961,"activeCount":8},[],{"trials":963,"activeCount":8},[964,968],{"nctId":919,"briefTitle":920,"status":60,"phases":965,"completion":922,"start":923,"enrollment":924,"conditions":966,"interventions":967},[37],[23],[912,927],{"nctId":929,"briefTitle":930,"status":60,"phases":969,"completion":922,"start":923,"enrollment":197,"conditions":970,"interventions":971},[37],[23],[912,927],{"trials":973,"activeCount":8},[974,978],{"nctId":937,"briefTitle":938,"status":60,"phases":975,"start":940,"enrollment":941,"conditions":976,"interventions":977},[38],[23],[912,927],{"nctId":945,"briefTitle":946,"status":60,"phases":979,"start":948,"enrollment":949,"conditions":980,"interventions":981},[37,38],[23],[912,927],{"trials":983,"activeCount":8},[],{"trials":985,"activeCount":8},[],{"trials":987,"activeCount":8},[],{"intervention":989,"totalTrials":232,"cells":990},"thalidomide",{"EARLY_PHASE1":991,"PHASE1":993,"PHASE2":995,"PHASE3":1023,"PHASE4":1025,"NA":1027},{"trials":992,"activeCount":8},[],{"trials":994,"activeCount":8},[],{"trials":996,"activeCount":8},[997,1004,1015],{"nctId":998,"briefTitle":999,"status":167,"phases":1000,"conditions":1001,"interventions":1003},"NCT00006198","Chronic Thalidomide Administration in Patients Undergoing Chemoembolization for Unresectable Hepatocellular Cancer",[38],[1002],"Liver Cancer",[989],{"nctId":1005,"briefTitle":1006,"status":60,"phases":1007,"completion":1008,"start":1009,"enrollment":1010,"conditions":1011,"interventions":1014},"NCT00004276","Phase II Placebo Controlled Study of Thalidomide in Patients With Mycobacterial and HIV Infections",[38],"1999-06","1990-09",50,[20,1012,1013],"Mycobacterium Infections","Tuberculosis",[989],{"nctId":1016,"briefTitle":1017,"status":167,"phases":1018,"conditions":1019,"interventions":1021},"NCT00006200","Thalidomide and Dacarbazine for Metastatic Melanoma",[38],[1020],"Melanoma",[989,1022],"dacarbazine",{"trials":1024,"activeCount":8},[],{"trials":1026,"activeCount":8},[],{"trials":1028,"activeCount":8},[],{"intervention":1030,"totalTrials":45,"cells":1031},"calcitonin",{"EARLY_PHASE1":1032,"PHASE1":1034,"PHASE2":1036,"PHASE3":1047,"PHASE4":1049,"NA":1051},{"trials":1033,"activeCount":8},[],{"trials":1035,"activeCount":8},[],{"trials":1037,"activeCount":8},[1038],{"nctId":1039,"briefTitle":1040,"status":60,"phases":1041,"start":1042,"enrollment":1043,"conditions":1044,"interventions":1046},"NCT00004358","Phase II Study of Calcitonin for Tumoral Calcinosis",[38],"1992-11",9,[1045],"Calcinosis",[1030],{"trials":1048,"activeCount":8},[],{"trials":1050,"activeCount":8},[],{"trials":1052,"activeCount":8},[],{"intervention":1054,"totalTrials":45,"cells":1055},"monoclonal factor IX replacement therapy",{"EARLY_PHASE1":1056,"PHASE1":1058,"PHASE2":1060,"PHASE3":1071,"PHASE4":1073,"NA":1075},{"trials":1057,"activeCount":8},[],{"trials":1059,"activeCount":8},[],{"trials":1061,"activeCount":8},[1062],{"nctId":1063,"briefTitle":1064,"status":60,"phases":1065,"start":1066,"enrollment":232,"conditions":1067,"interventions":1070},"NCT00004801","Phase I\u002FII Study of Monoclonal Factor IX Concentrate for Factor IX Deficiency",[37,38],"1992-03",[1068,1069],"Hemophilia B","Factor IX Deficiency",[1054],{"trials":1072,"activeCount":8},[],{"trials":1074,"activeCount":8},[],{"trials":1076,"activeCount":8},[],{"intervention":1078,"totalTrials":45,"cells":1079},"Clomipramine",{"EARLY_PHASE1":1080,"PHASE1":1082,"PHASE2":1084,"PHASE3":1095,"PHASE4":1097,"NA":1099},{"trials":1081,"activeCount":8},[],{"trials":1083,"activeCount":8},[],{"trials":1085,"activeCount":8},[1086],{"nctId":1087,"briefTitle":1088,"status":167,"phases":1089,"start":1090,"enrollment":1091,"conditions":1092,"interventions":1094},"NCT00004310","Phase II Randomized Study of Intravenous Versus Oral Clomipramine in Patients With Obsessive Compulsive Disorder",[38],"1999-10",76,[1093],"Obsessive-Compulsive Disorder",[1078],{"trials":1096,"activeCount":8},[],{"trials":1098,"activeCount":8},[],{"trials":1100,"activeCount":8},[],{"intervention":1102,"totalTrials":45,"cells":1103},"131I-MIBG",{"EARLY_PHASE1":1104,"PHASE1":1106,"PHASE2":1108,"PHASE3":1117,"PHASE4":1119,"NA":1121},{"trials":1105,"activeCount":8},[],{"trials":1107,"activeCount":8},[],{"trials":1109,"activeCount":8},[1110],{"nctId":1111,"briefTitle":1112,"status":167,"phases":1113,"conditions":1114,"interventions":1116},"NCT00013806","CHP677: I-Metaiodobenzylguanidine (I-MIBG) Therapy for Refractory Neuroblastoma: a Phase II Study",[38],[1115],"Neuroblastoma",[1102],{"trials":1118,"activeCount":8},[],{"trials":1120,"activeCount":8},[],{"trials":1122,"activeCount":8},[],{"intervention":1124,"totalTrials":45,"cells":1125},"hOKT3gamma1",{"EARLY_PHASE1":1126,"PHASE1":1128,"PHASE2":1130,"PHASE3":1142,"PHASE4":1144,"NA":1146},{"trials":1127,"activeCount":8},[],{"trials":1129,"activeCount":8},[],{"trials":1131,"activeCount":8},[1132],{"nctId":1133,"briefTitle":1134,"status":167,"phases":1135,"conditions":1136,"interventions":1141},"NCT00008801","hOKT3gamma1 (Ala-Ala) for the Prevention of Human Islet Allograft Failure",[37,38],[1137,1138,1139,1140],"Diabetes Mellitus, Insulin-Dependent","Diabetes Mellitus, Experimental","Transplantation, Homologous","Islets of Langerhans Transplantation",[1124],{"trials":1143,"activeCount":8},[],{"trials":1145,"activeCount":8},[],{"trials":1147,"activeCount":8},[],{"intervention":1149,"totalTrials":45,"cells":1150},"filgrastim",{"EARLY_PHASE1":1151,"PHASE1":1153,"PHASE2":1155,"PHASE3":1168,"PHASE4":1170,"NA":1172},{"trials":1152,"activeCount":8},[],{"trials":1154,"activeCount":8},[],{"trials":1156,"activeCount":8},[1157],{"nctId":1158,"briefTitle":1159,"status":60,"phases":1160,"start":1161,"enrollment":197,"conditions":1162,"interventions":1167},"NCT00004787","Phase II Pilot Study of Granulocyte Colony-Stimulating Factor for Inherited Bone Marrow Failure Syndromes",[38],"1994-12",[1163,1164,1165,1166],"Shwachman Syndrome","Fanconi's Anemia","Dyskeratosis Congenita","Thrombocytopenia",[1149],{"trials":1169,"activeCount":8},[],{"trials":1171,"activeCount":8},[],{"trials":1173,"activeCount":8},[],{"intervention":1175,"totalTrials":45,"cells":1176},"Creatinine",{"EARLY_PHASE1":1177,"PHASE1":1179,"PHASE2":1181,"PHASE3":1190,"PHASE4":1192,"NA":1194},{"trials":1178,"activeCount":8},[],{"trials":1180,"activeCount":8},[],{"trials":1182,"activeCount":8},[1183],{"nctId":1184,"briefTitle":1185,"status":60,"phases":1186,"conditions":1187,"interventions":1189},"NCT00005766","Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis",[38],[1188],"Amyotrophic Lateral Sclerosis",[1175],{"trials":1191,"activeCount":8},[],{"trials":1193,"activeCount":8},[],{"trials":1195,"activeCount":8},[],{"intervention":1197,"totalTrials":45,"cells":1198},"cladribine",{"EARLY_PHASE1":1199,"PHASE1":1201,"PHASE2":1203,"PHASE3":1212,"PHASE4":1214,"NA":1216},{"trials":1200,"activeCount":8},[],{"trials":1202,"activeCount":8},[],{"trials":1204,"activeCount":8},[1205],{"nctId":1206,"briefTitle":1207,"status":60,"phases":1208,"start":1161,"enrollment":28,"conditions":1209,"interventions":1211},"NCT00004762","Phase II Pilot Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) for Early Stage Primary Sclerosing Cholangitis",[38],[1210],"Cholangitis, Sclerosing",[1197],{"trials":1213,"activeCount":8},[],{"trials":1215,"activeCount":8},[],{"trials":1217,"activeCount":8},[],{"intervention":1219,"totalTrials":45,"cells":1220},"aminomidazole carboxamide riboside",{"EARLY_PHASE1":1221,"PHASE1":1223,"PHASE2":1225,"PHASE3":1234,"PHASE4":1236,"NA":1238},{"trials":1222,"activeCount":8},[],{"trials":1224,"activeCount":8},[],{"trials":1226,"activeCount":8},[1227],{"nctId":1228,"briefTitle":1229,"status":60,"phases":1230,"start":291,"enrollment":276,"conditions":1231,"interventions":1233},"NCT00004314","Phase II Pilot Study of Aminoimidazole Carboxamide Riboside (AICAR), a Precursor of Purine Synthesis, for Lesch-Nyhan Disease",[38],[1232],"Lesch-Nyhan Syndrome",[1219],{"trials":1235,"activeCount":8},[],{"trials":1237,"activeCount":8},[],{"trials":1239,"activeCount":8},[],{"intervention":1241,"totalTrials":45,"cells":1242},"octreotide",{"EARLY_PHASE1":1243,"PHASE1":1245,"PHASE2":1247,"PHASE3":1257,"PHASE4":1259,"NA":1261},{"trials":1244,"activeCount":8},[],{"trials":1246,"activeCount":8},[],{"trials":1248,"activeCount":8},[1249],{"nctId":1250,"briefTitle":1251,"status":60,"phases":1252,"start":1253,"enrollment":18,"conditions":1254,"interventions":1256},"NCT00004327","Phase II Pilot Study of Octreotide, a Somatostatin Octapeptide Analog, for Gastrointestinal Hemorrhage in Hormone-Refractory Hereditary Hemorrhagic Telangiectasia and Senile Ectasia",[38],"1995-01",[647,1255],"Ectasia",[1241],{"trials":1258,"activeCount":8},[],{"trials":1260,"activeCount":8},[],{"trials":1262,"activeCount":8},[],{"intervention":1264,"totalTrials":45,"cells":1265},"mucoid exopolysaccharide P. aeruginosa immune globulin IV",{"EARLY_PHASE1":1266,"PHASE1":1268,"PHASE2":1270,"PHASE3":1281,"PHASE4":1283,"NA":1285},{"trials":1267,"activeCount":8},[],{"trials":1269,"activeCount":8},[],{"trials":1271,"activeCount":8},[1272],{"nctId":1273,"briefTitle":1274,"status":60,"phases":1275,"start":1276,"enrollment":1277,"conditions":1278,"interventions":1280},"NCT00004747","Phase II Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Mucoid Exopolysaccharide Pseudomonas Aeruginosa Immune Globulin for Cystic Fibrosis",[38],"1995-07",170,[14,1279],"Bacterial Infections",[1264],{"trials":1282,"activeCount":8},[],{"trials":1284,"activeCount":8},[],{"trials":1286,"activeCount":8},[],{"intervention":1288,"totalTrials":45,"cells":1289},"Rifampin",{"EARLY_PHASE1":1290,"PHASE1":1292,"PHASE2":1294,"PHASE3":1303,"PHASE4":1305,"NA":1307},{"trials":1291,"activeCount":8},[],{"trials":1293,"activeCount":8},[],{"trials":1295,"activeCount":8},[1296],{"nctId":1297,"briefTitle":1298,"status":60,"phases":1299,"enrollment":207,"conditions":1300,"interventions":1301},"NCT00043264","Antibiotic Treatment Trial Directed Against Chlamydia Pneumonia in Multiple Sclerosis",[38],[32],[1288,1302],"Azithromycin",{"trials":1304,"activeCount":8},[],{"trials":1306,"activeCount":8},[],{"trials":1308,"activeCount":8},[],{"intervention":1302,"totalTrials":45,"cells":1310},{"EARLY_PHASE1":1311,"PHASE1":1313,"PHASE2":1315,"PHASE3":1321,"PHASE4":1323,"NA":1325},{"trials":1312,"activeCount":8},[],{"trials":1314,"activeCount":8},[],{"trials":1316,"activeCount":8},[1317],{"nctId":1297,"briefTitle":1298,"status":60,"phases":1318,"enrollment":207,"conditions":1319,"interventions":1320},[38],[32],[1288,1302],{"trials":1322,"activeCount":8},[],{"trials":1324,"activeCount":8},[],{"trials":1326,"activeCount":8},[],{"intervention":1328,"totalTrials":45,"cells":1329},"olsalazine",{"EARLY_PHASE1":1330,"PHASE1":1332,"PHASE2":1334,"PHASE3":1345,"PHASE4":1347,"NA":1349},{"trials":1331,"activeCount":8},[],{"trials":1333,"activeCount":8},[],{"trials":1335,"activeCount":8},[1336],{"nctId":1337,"briefTitle":1338,"status":60,"phases":1339,"completion":1340,"start":1341,"enrollment":33,"conditions":1342,"interventions":1344},"NCT00004288","Phase II Pilot Study of Olsalazine for Ankylosing Spondylitis",[38],"1999-12","1996-05",[1343],"Ankylosing Spondylitis",[1328],{"trials":1346,"activeCount":8},[],{"trials":1348,"activeCount":8},[],{"trials":1350,"activeCount":8},[],{"intervention":1352,"totalTrials":45,"cells":1353},"Sodium Benzoate",{"EARLY_PHASE1":1354,"PHASE1":1356,"PHASE2":1358,"PHASE3":1370,"PHASE4":1372,"NA":1374},{"trials":1355,"activeCount":8},[],{"trials":1357,"activeCount":8},[],{"trials":1359,"activeCount":8},[1360],{"nctId":1361,"briefTitle":1362,"status":60,"phases":1363,"start":1364,"enrollment":197,"conditions":1365,"interventions":1367},"NCT00004767","Phase II Study of Sodium Phenylbutyrate, Sodium Benzoate, Sodium Phenylacetate, and Dietary Intervention for Urea Cycle Disorders",[38],"1985-01",[1366],"Amino Acid Metabolism, Inborn Errors",[1352,1368,1369],"Sodium Phenylacetate","Sodium Phenylbutyrate",{"trials":1371,"activeCount":8},[],{"trials":1373,"activeCount":8},[],{"trials":1375,"activeCount":8},[],{"intervention":1368,"totalTrials":45,"cells":1377},{"EARLY_PHASE1":1378,"PHASE1":1380,"PHASE2":1382,"PHASE3":1388,"PHASE4":1390,"NA":1392},{"trials":1379,"activeCount":8},[],{"trials":1381,"activeCount":8},[],{"trials":1383,"activeCount":8},[1384],{"nctId":1361,"briefTitle":1362,"status":60,"phases":1385,"start":1364,"enrollment":197,"conditions":1386,"interventions":1387},[38],[1366],[1352,1368,1369],{"trials":1389,"activeCount":8},[],{"trials":1391,"activeCount":8},[],{"trials":1393,"activeCount":8},[],{"intervention":1369,"totalTrials":45,"cells":1395},{"EARLY_PHASE1":1396,"PHASE1":1398,"PHASE2":1400,"PHASE3":1406,"PHASE4":1408,"NA":1410},{"trials":1397,"activeCount":8},[],{"trials":1399,"activeCount":8},[],{"trials":1401,"activeCount":8},[1402],{"nctId":1361,"briefTitle":1362,"status":60,"phases":1403,"start":1364,"enrollment":197,"conditions":1404,"interventions":1405},[38],[1366],[1352,1368,1369],{"trials":1407,"activeCount":8},[],{"trials":1409,"activeCount":8},[],{"trials":1411,"activeCount":8},[],{"intervention":1413,"totalTrials":45,"cells":1414},"Nifedipine",{"EARLY_PHASE1":1415,"PHASE1":1417,"PHASE2":1419,"PHASE3":1428,"PHASE4":1430,"NA":1432},{"trials":1416,"activeCount":8},[],{"trials":1418,"activeCount":8},[],{"trials":1420,"activeCount":8},[1421],{"nctId":1422,"briefTitle":1423,"status":60,"phases":1424,"conditions":1425,"interventions":1427},"NCT00000102","Congenital Adrenal Hyperplasia: Calcium Channels as Therapeutic Targets",[37,38],[1426],"Congenital Adrenal Hyperplasia",[1413],{"trials":1429,"activeCount":8},[],{"trials":1431,"activeCount":8},[],{"trials":1433,"activeCount":8},[],{"intervention":1435,"totalTrials":45,"cells":1436},"carbamazepine",{"EARLY_PHASE1":1437,"PHASE1":1439,"PHASE2":1441,"PHASE3":1454,"PHASE4":1456,"NA":1458},{"trials":1438,"activeCount":8},[],{"trials":1440,"activeCount":8},[],{"trials":1442,"activeCount":8},[1443],{"nctId":1444,"briefTitle":1445,"status":60,"phases":1446,"start":753,"enrollment":9,"conditions":1447,"interventions":1449},"NCT00004758","Phase II Randomized Study of Early Surgery Vs Multiple Sequential Antiepileptic Drug Therapy for Infantile Spasms Refractory to Standard Treatment",[38],[1448,108],"Spasms, Infantile",[1435,1450,1451,1452,1453],"corticotropin","nitrazepam","pyridoxine","valproic acid",{"trials":1455,"activeCount":8},[],{"trials":1457,"activeCount":8},[],{"trials":1459,"activeCount":8},[],{"intervention":1451,"totalTrials":45,"cells":1461},{"EARLY_PHASE1":1462,"PHASE1":1464,"PHASE2":1466,"PHASE3":1472,"PHASE4":1474,"NA":1476},{"trials":1463,"activeCount":8},[],{"trials":1465,"activeCount":8},[],{"trials":1467,"activeCount":8},[1468],{"nctId":1444,"briefTitle":1445,"status":60,"phases":1469,"start":753,"enrollment":9,"conditions":1470,"interventions":1471},[38],[1448,108],[1435,1450,1451,1452,1453],{"trials":1473,"activeCount":8},[],{"trials":1475,"activeCount":8},[],{"trials":1477,"activeCount":8},[],{"intervention":1452,"totalTrials":45,"cells":1479},{"EARLY_PHASE1":1480,"PHASE1":1482,"PHASE2":1484,"PHASE3":1490,"PHASE4":1492,"NA":1494},{"trials":1481,"activeCount":8},[],{"trials":1483,"activeCount":8},[],{"trials":1485,"activeCount":8},[1486],{"nctId":1444,"briefTitle":1445,"status":60,"phases":1487,"start":753,"enrollment":9,"conditions":1488,"interventions":1489},[38],[1448,108],[1435,1450,1451,1452,1453],{"trials":1491,"activeCount":8},[],{"trials":1493,"activeCount":8},[],{"trials":1495,"activeCount":8},[],{"intervention":1453,"totalTrials":45,"cells":1497},{"EARLY_PHASE1":1498,"PHASE1":1500,"PHASE2":1502,"PHASE3":1508,"PHASE4":1510,"NA":1512},{"trials":1499,"activeCount":8},[],{"trials":1501,"activeCount":8},[],{"trials":1503,"activeCount":8},[1504],{"nctId":1444,"briefTitle":1445,"status":60,"phases":1505,"start":753,"enrollment":9,"conditions":1506,"interventions":1507},[38],[1448,108],[1435,1450,1451,1452,1453],{"trials":1509,"activeCount":8},[],{"trials":1511,"activeCount":8},[],{"trials":1513,"activeCount":8},[],{"intervention":1515,"totalTrials":45,"cells":1516},"Hormone Replacement Therapy",{"EARLY_PHASE1":1517,"PHASE1":1519,"PHASE2":1521,"PHASE3":1530,"PHASE4":1532,"NA":1534},{"trials":1518,"activeCount":8},[],{"trials":1520,"activeCount":8},[],{"trials":1522,"activeCount":8},[1523],{"nctId":1524,"briefTitle":1525,"status":167,"phases":1526,"conditions":1527,"interventions":1529},"NCT00005769","Hormone Replacement Therapy and Insulin Action: A Double-Blind, Parallel, Placebo-Controlled Hormone Intervention Study in Postmenopausal Women",[38],[1528],"Menopause",[1515],{"trials":1531,"activeCount":8},[],{"trials":1533,"activeCount":8},[],{"trials":1535,"activeCount":8},[],{"intervention":1537,"totalTrials":45,"cells":1538},"SDZ MSL-109",{"EARLY_PHASE1":1539,"PHASE1":1541,"PHASE2":1543,"PHASE3":1552,"PHASE4":1554,"NA":1556},{"trials":1540,"activeCount":8},[],{"trials":1542,"activeCount":8},[],{"trials":1544,"activeCount":8},[1545],{"nctId":1546,"briefTitle":1547,"status":60,"phases":1548,"start":149,"conditions":1549,"interventions":1551},"NCT00004642","Phase I\u002FII Study of Human Anti-Cytomegalovirus (CMV) Monoclonal Antibody MSL-109 in Newborns With Symptomatic Congenital CMV Infection Without Central Nervous System Disease",[37,38],[1550],"Cytomegalovirus Infections",[1537],{"trials":1553,"activeCount":8},[],{"trials":1555,"activeCount":8},[],{"trials":1557,"activeCount":8},[],{"intervention":1559,"totalTrials":45,"cells":1560},"Aricept",{"EARLY_PHASE1":1561,"PHASE1":1563,"PHASE2":1565,"PHASE3":1576,"PHASE4":1578,"NA":1580},{"trials":1562,"activeCount":8},[],{"trials":1564,"activeCount":8},[],{"trials":1566,"activeCount":8},[1567],{"nctId":1568,"briefTitle":1569,"status":167,"phases":1570,"conditions":1571,"interventions":1574},"NCT00031018","Prevention of Cognitive Decline in Alzheimer's Disease by Ingested Interferon Alpha",[38],[1572,1573],"Memory Disorders","Alzheimer's Disease",[1559,1575],"IFN-alpha2A",{"trials":1577,"activeCount":8},[],{"trials":1579,"activeCount":8},[],{"trials":1581,"activeCount":8},[],{"intervention":1575,"totalTrials":45,"cells":1583},{"EARLY_PHASE1":1584,"PHASE1":1586,"PHASE2":1588,"PHASE3":1594,"PHASE4":1596,"NA":1598},{"trials":1585,"activeCount":8},[],{"trials":1587,"activeCount":8},[],{"trials":1589,"activeCount":8},[1590],{"nctId":1568,"briefTitle":1569,"status":167,"phases":1591,"conditions":1592,"interventions":1593},[38],[1572,1573],[1559,1575],{"trials":1595,"activeCount":8},[],{"trials":1597,"activeCount":8},[],{"trials":1599,"activeCount":8},[],{"intervention":1601,"totalTrials":45,"cells":1602},"Doxil",{"EARLY_PHASE1":1603,"PHASE1":1605,"PHASE2":1607,"PHASE3":1617,"PHASE4":1619,"NA":1621},{"trials":1604,"activeCount":8},[],{"trials":1606,"activeCount":8},[],{"trials":1608,"activeCount":8},[1609],{"nctId":1610,"briefTitle":1611,"status":167,"phases":1612,"start":1613,"conditions":1614,"interventions":1616},"NCT00006433","Phase I\u002FII Trial of Doxil and Hyperthermia for Breast Cancer Patients With Chest Wall Recurrence or Stage IV Disease With Locally Advanced Breast Cancer",[38],"2000-01",[1615],"Breast Cancer",[1601],{"trials":1618,"activeCount":8},[],{"trials":1620,"activeCount":8},[],{"trials":1622,"activeCount":8},[],{"intervention":1624,"totalTrials":45,"cells":1625},"cidofovir",{"EARLY_PHASE1":1626,"PHASE1":1628,"PHASE2":1630,"PHASE3":1641,"PHASE4":1643,"NA":1645},{"trials":1627,"activeCount":8},[],{"trials":1629,"activeCount":8},[],{"trials":1631,"activeCount":8},[1632],{"nctId":1633,"briefTitle":1634,"status":60,"phases":1635,"start":1636,"enrollment":256,"conditions":1637,"interventions":1640},"NCT00004794","Phase II Randomized Study of Cidofovir for Peripheral Cytomegalovirus Retinitis",[38],"1995-03",[1638,1639],"Cytomegalovirus Retinitis","Acquired Immunodeficiency Syndrome",[1624],{"trials":1642,"activeCount":8},[],{"trials":1644,"activeCount":8},[],{"trials":1646,"activeCount":8},[],{"intervention":1648,"totalTrials":45,"cells":1649},"relaxin",{"EARLY_PHASE1":1650,"PHASE1":1652,"PHASE2":1654,"PHASE3":1664,"PHASE4":1666,"NA":1668},{"trials":1651,"activeCount":8},[],{"trials":1653,"activeCount":8},[],{"trials":1655,"activeCount":8},[1656],{"nctId":1657,"briefTitle":1658,"status":60,"phases":1659,"completion":1660,"start":1661,"enrollment":45,"conditions":1662,"interventions":1663},"NCT00004380","Phase II Study of Recombinant Relaxin for Progressive Systemic Sclerosis",[38],"1997-12","1991-12",[779],[1648],{"trials":1665,"activeCount":8},[],{"trials":1667,"activeCount":8},[],{"trials":1669,"activeCount":8},[],{"intervention":1671,"totalTrials":45,"cells":1672},"Rituxan",{"EARLY_PHASE1":1673,"PHASE1":1675,"PHASE2":1677,"PHASE3":1686,"PHASE4":1688,"NA":1690},{"trials":1674,"activeCount":8},[],{"trials":1676,"activeCount":8},[],{"trials":1678,"activeCount":8},[1679],{"nctId":1680,"briefTitle":1681,"status":167,"phases":1682,"conditions":1683,"interventions":1685},"NCT00006072","A Study of Rituxan in the Treatment of Polyneuropathies Associated With Serum IgM Autoantibodies",[38],[1684],"Peripheral Neuropathy",[1671],{"trials":1687,"activeCount":8},[],{"trials":1689,"activeCount":8},[],{"trials":1691,"activeCount":8},[],{"intervention":1693,"totalTrials":45,"cells":1694},"cytarabine",{"EARLY_PHASE1":1695,"PHASE1":1697,"PHASE2":1699,"PHASE3":1708,"PHASE4":1710,"NA":1712},{"trials":1696,"activeCount":8},[],{"trials":1698,"activeCount":8},[],{"trials":1700,"activeCount":8},[1701],{"nctId":1702,"briefTitle":1703,"status":60,"phases":1704,"start":149,"enrollment":354,"conditions":1705,"interventions":1707},"NCT00004643","Phase II Pilot Study of Cytarabine for Refractory Systemic Lupus Erythematosus",[38],[1706],"Lupus Erythematosus, Systemic",[1693],{"trials":1709,"activeCount":8},[],{"trials":1711,"activeCount":8},[],{"trials":1713,"activeCount":8},[],{"intervention":1715,"totalTrials":45,"cells":1716},"Creatine",{"EARLY_PHASE1":1717,"PHASE1":1719,"PHASE2":1721,"PHASE3":1729,"PHASE4":1731,"NA":1733},{"trials":1718,"activeCount":8},[],{"trials":1720,"activeCount":8},[],{"trials":1722,"activeCount":8},[1723],{"nctId":1724,"briefTitle":1725,"status":60,"phases":1726,"conditions":1727,"interventions":1728},"NCT00005674","Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis [ALS]",[38],[1188],[1715],{"trials":1730,"activeCount":8},[],{"trials":1732,"activeCount":8},[],{"trials":1734,"activeCount":8},[],{"intervention":1736,"totalTrials":45,"cells":1737},"lactulose",{"EARLY_PHASE1":1738,"PHASE1":1740,"PHASE2":1742,"PHASE3":1755,"PHASE4":1757,"NA":1759},{"trials":1739,"activeCount":8},[],{"trials":1741,"activeCount":8},[],{"trials":1743,"activeCount":8},[1744],{"nctId":1745,"briefTitle":1746,"status":60,"phases":1747,"completion":1748,"start":1749,"enrollment":1750,"conditions":1751,"interventions":1754},"NCT00004796","Phase II Study of Lactulose and Circadian Rhythms in Patients With Cirrhosis",[38],"1997-02","1994-11",16,[1752,1753,385],"Portal Hypertension","Hepatic Encephalopathy",[1736],{"trials":1756,"activeCount":8},[],{"trials":1758,"activeCount":8},[],{"trials":1760,"activeCount":8},[],{"intervention":358,"totalTrials":45,"cells":1762},{"EARLY_PHASE1":1763,"PHASE1":1765,"PHASE2":1767,"PHASE3":1773,"PHASE4":1775,"NA":1777},{"trials":1764,"activeCount":8},[],{"trials":1766,"activeCount":8},[],{"trials":1768,"activeCount":8},[1769],{"nctId":351,"briefTitle":352,"status":60,"phases":1770,"start":149,"enrollment":354,"conditions":1771,"interventions":1772},[38],[356],[358,359,360,361,261,337],{"trials":1774,"activeCount":8},[],{"trials":1776,"activeCount":8},[],{"trials":1778,"activeCount":8},[],{"intervention":359,"totalTrials":45,"cells":1780},{"EARLY_PHASE1":1781,"PHASE1":1783,"PHASE2":1785,"PHASE3":1791,"PHASE4":1793,"NA":1795},{"trials":1782,"activeCount":8},[],{"trials":1784,"activeCount":8},[],{"trials":1786,"activeCount":8},[1787],{"nctId":351,"briefTitle":352,"status":60,"phases":1788,"start":149,"enrollment":354,"conditions":1789,"interventions":1790},[38],[356],[358,359,360,361,261,337],{"trials":1792,"activeCount":8},[],{"trials":1794,"activeCount":8},[],{"trials":1796,"activeCount":8},[],{"intervention":360,"totalTrials":45,"cells":1798},{"EARLY_PHASE1":1799,"PHASE1":1801,"PHASE2":1803,"PHASE3":1809,"PHASE4":1811,"NA":1813},{"trials":1800,"activeCount":8},[],{"trials":1802,"activeCount":8},[],{"trials":1804,"activeCount":8},[1805],{"nctId":351,"briefTitle":352,"status":60,"phases":1806,"start":149,"enrollment":354,"conditions":1807,"interventions":1808},[38],[356],[358,359,360,361,261,337],{"trials":1810,"activeCount":8},[],{"trials":1812,"activeCount":8},[],{"trials":1814,"activeCount":8},[],{"intervention":361,"totalTrials":45,"cells":1816},{"EARLY_PHASE1":1817,"PHASE1":1819,"PHASE2":1821,"PHASE3":1827,"PHASE4":1829,"NA":1831},{"trials":1818,"activeCount":8},[],{"trials":1820,"activeCount":8},[],{"trials":1822,"activeCount":8},[1823],{"nctId":351,"briefTitle":352,"status":60,"phases":1824,"start":149,"enrollment":354,"conditions":1825,"interventions":1826},[38],[356],[358,359,360,361,261,337],{"trials":1828,"activeCount":8},[],{"trials":1830,"activeCount":8},[],{"trials":1832,"activeCount":8},[],{"intervention":1834,"totalTrials":45,"cells":1835},"midodrine",{"EARLY_PHASE1":1836,"PHASE1":1838,"PHASE2":1840,"PHASE3":1850,"PHASE4":1852,"NA":1854},{"trials":1837,"activeCount":8},[],{"trials":1839,"activeCount":8},[],{"trials":1841,"activeCount":8},[1842],{"nctId":1843,"briefTitle":1844,"status":60,"phases":1845,"start":1846,"enrollment":130,"conditions":1847,"interventions":1849},"NCT00004268","Phase II Study of Midodrine for Neurogenic Orthostatic Hypotension",[38],"2001-04",[1848],"Orthostatic Hypotension",[1834],{"trials":1851,"activeCount":8},[],{"trials":1853,"activeCount":8},[],{"trials":1855,"activeCount":8},[],{"intervention":1857,"totalTrials":45,"cells":1858},"Ethinyl estradiol\u002Fnorethindrone",{"EARLY_PHASE1":1859,"PHASE1":1861,"PHASE2":1863,"PHASE3":1875,"PHASE4":1877,"NA":1879},{"trials":1860,"activeCount":8},[],{"trials":1862,"activeCount":8},[],{"trials":1864,"activeCount":8},[1865],{"nctId":1866,"briefTitle":1867,"status":60,"phases":1868,"start":1869,"enrollment":1870,"conditions":1871,"interventions":1873},"NCT00004763","Phase II Randomized Study of Leuprolide Vs Oral Contraceptive Therapy Vs Leuprolide and Oral Contraceptive Therapy for Ovarian Hyperandrogenism",[38],"1993-01",45,[1872],"Hyperandrogenism",[1874,1857],"leuprolide",{"trials":1876,"activeCount":8},[],{"trials":1878,"activeCount":8},[],{"trials":1880,"activeCount":8},[],{"intervention":1882,"totalTrials":45,"cells":1883},"pimozide",{"EARLY_PHASE1":1884,"PHASE1":1886,"PHASE2":1888,"PHASE3":1897,"PHASE4":1899,"NA":1901},{"trials":1885,"activeCount":8},[],{"trials":1887,"activeCount":8},[],{"trials":1889,"activeCount":8},[1890],{"nctId":1891,"briefTitle":1892,"status":60,"phases":1893,"start":1894,"enrollment":197,"conditions":1895,"interventions":1896},"NCT00004652","Phase II Pilot Controlled Study of Short Vs Longer Term Pimozide (Orap) Therapy in Tourette Syndrome",[38],"1993-02",[27],[1882],{"trials":1898,"activeCount":8},[],{"trials":1900,"activeCount":8},[],{"trials":1902,"activeCount":8},[],{"intervention":1904,"totalTrials":45,"cells":1905},"chenodeoxycholic acid",{"EARLY_PHASE1":1906,"PHASE1":1908,"PHASE2":1910,"PHASE3":1920,"PHASE4":1922,"NA":1924},{"trials":1907,"activeCount":8},[],{"trials":1909,"activeCount":8},[],{"trials":1911,"activeCount":8},[1912],{"nctId":1913,"briefTitle":1914,"status":167,"phases":1915,"start":644,"enrollment":28,"conditions":1916,"interventions":1918},"NCT00004346","Phase II Study of Cholesterol- and Cholestanol-Free Diet, Lovastatin, and Chenodeoxycholic Acid for Cerebrotendinous Xanthomatosis",[38],[1917],"Cerebrotendinous Xanthomatosis",[1904,1919],"lovastatin",{"trials":1921,"activeCount":8},[],{"trials":1923,"activeCount":8},[],{"trials":1925,"activeCount":8},[],{"intervention":1919,"totalTrials":45,"cells":1927},{"EARLY_PHASE1":1928,"PHASE1":1930,"PHASE2":1932,"PHASE3":1938,"PHASE4":1940,"NA":1942},{"trials":1929,"activeCount":8},[],{"trials":1931,"activeCount":8},[],{"trials":1933,"activeCount":8},[1934],{"nctId":1913,"briefTitle":1914,"status":167,"phases":1935,"start":644,"enrollment":28,"conditions":1936,"interventions":1937},[38],[1917],[1904,1919],{"trials":1939,"activeCount":8},[],{"trials":1941,"activeCount":8},[],{"trials":1943,"activeCount":8},[],{"intervention":1945,"totalTrials":45,"cells":1946},"interferon alpha",{"EARLY_PHASE1":1947,"PHASE1":1949,"PHASE2":1951,"PHASE3":1960,"PHASE4":1962,"NA":1964},{"trials":1948,"activeCount":8},[],{"trials":1950,"activeCount":8},[],{"trials":1952,"activeCount":8},[1953],{"nctId":1954,"briefTitle":1955,"status":167,"phases":1956,"conditions":1957,"interventions":1959},"NCT00005665","Ingested Interferon Alpha: Prolongation or Permanence of the \"Honeymoon\" Phase in Newly Diagnosed Type 1 Diabetes Mellitus",[38],[1958],"Diabetes Mellitus, Type 1",[1945],{"trials":1961,"activeCount":8},[],{"trials":1963,"activeCount":8},[],{"trials":1965,"activeCount":8},[],{"intervention":1967,"totalTrials":45,"cells":1968},"hydrocortisone",{"EARLY_PHASE1":1969,"PHASE1":1971,"PHASE2":1973,"PHASE3":1982,"PHASE4":1984,"NA":1986},{"trials":1970,"activeCount":8},[],{"trials":1972,"activeCount":8},[],{"trials":1974,"activeCount":8},[1975],{"nctId":1976,"briefTitle":1977,"status":60,"phases":1978,"start":1979,"enrollment":207,"conditions":1980,"interventions":1981},"NCT00004669","Phase II Pilot Study of Early Cortisol Replacement to Prevent Bronchopulmonary Dysplasia",[38],"1996-06",[335],[1967],{"trials":1983,"activeCount":8},[],{"trials":1985,"activeCount":8},[],{"trials":1987,"activeCount":8},[],{"intervention":1989,"totalTrials":45,"cells":1990},"leuprolide acetate",{"EARLY_PHASE1":1991,"PHASE1":1993,"PHASE2":1995,"PHASE3":2007,"PHASE4":2009,"NA":2011},{"trials":1992,"activeCount":8},[],{"trials":1994,"activeCount":8},[],{"trials":1996,"activeCount":8},[1997],{"nctId":1998,"briefTitle":1999,"status":60,"phases":2000,"completion":644,"start":2001,"conditions":2002,"interventions":2005},"NCT00004311","Phase II Study of the Effect of Leuprolide Acetate and Spironolactone on Insulin Resistance in Hyperandrogenic Women With Polycystic Ovarian Disease or Hyperandrogenism Insulin Resistance Acanthosis Nigricans Syndrome",[38],"1989-07",[2003,2004],"Acanthosis Nigricans","Polycystic Ovary Syndrome",[1989,2006],"spironolactone",{"trials":2008,"activeCount":8},[],{"trials":2010,"activeCount":8},[],{"trials":2012,"activeCount":8},[],{"intervention":2006,"totalTrials":45,"cells":2014},{"EARLY_PHASE1":2015,"PHASE1":2017,"PHASE2":2019,"PHASE3":2025,"PHASE4":2027,"NA":2029},{"trials":2016,"activeCount":8},[],{"trials":2018,"activeCount":8},[],{"trials":2020,"activeCount":8},[2021],{"nctId":1998,"briefTitle":1999,"status":60,"phases":2022,"completion":644,"start":2001,"conditions":2023,"interventions":2024},[38],[2003,2004],[1989,2006],{"trials":2026,"activeCount":8},[],{"trials":2028,"activeCount":8},[],{"trials":2030,"activeCount":8},[],{"intervention":2032,"totalTrials":45,"cells":2033},"glucocerebrosidase",{"EARLY_PHASE1":2034,"PHASE1":2036,"PHASE2":2038,"PHASE3":2047,"PHASE4":2049,"NA":2051},{"trials":2035,"activeCount":8},[],{"trials":2037,"activeCount":8},[],{"trials":2039,"activeCount":8},[2040],{"nctId":2041,"briefTitle":2042,"status":167,"phases":2043,"start":290,"enrollment":924,"conditions":2044,"interventions":2046},"NCT00004293","Phase II Study of Glucocerebrosidase in Patients With Gaucher Disease",[38],[2045],"Gaucher's Disease",[2032],{"trials":2048,"activeCount":8},[],{"trials":2050,"activeCount":8},[],{"trials":2052,"activeCount":8},[],{"intervention":2054,"totalTrials":45,"cells":2055},"itraconazole",{"EARLY_PHASE1":2056,"PHASE1":2058,"PHASE2":2060,"PHASE3":2072,"PHASE4":2074,"NA":2076},{"trials":2057,"activeCount":8},[],{"trials":2059,"activeCount":8},[],{"trials":2061,"activeCount":8},[2062],{"nctId":2063,"briefTitle":2064,"status":60,"phases":2065,"start":2066,"enrollment":21,"conditions":2067,"interventions":2071},"NCT00004811","Phase I\u002FII Study of Itraconazole for Blastomycosis, Histoplasmosis, and Sporotrichosis",[37,38],"1985-03",[2068,2069,2070],"Histoplasmosis","Sporotrichosis","Blastomycosis",[2054],{"trials":2073,"activeCount":8},[],{"trials":2075,"activeCount":8},[],{"trials":2077,"activeCount":8},[],{"intervention":2079,"totalTrials":45,"cells":2080},"polystyrene sulfonate",{"EARLY_PHASE1":2081,"PHASE1":2083,"PHASE2":2085,"PHASE3":2096,"PHASE4":2098,"NA":2100},{"trials":2082,"activeCount":8},[],{"trials":2084,"activeCount":8},[],{"trials":2086,"activeCount":8},[2087],{"nctId":2088,"briefTitle":2089,"status":60,"phases":2090,"start":2091,"enrollment":45,"conditions":2092,"interventions":2094},"NCT00004328","Phase II Study of the Pathophysiology and Treatment With Enalapril and Polystyrene Sulfonate for Pseudohypoaldosteronism, Type I",[38],"1992-12",[2093],"Pseudohypoaldosteronism",[2095,2079],"enalapril",{"trials":2097,"activeCount":8},[],{"trials":2099,"activeCount":8},[],{"trials":2101,"activeCount":8},[],{"intervention":2103,"totalTrials":45,"cells":2104},"Donepezil",{"EARLY_PHASE1":2105,"PHASE1":2107,"PHASE2":2109,"PHASE3":2122,"PHASE4":2124,"NA":2126},{"trials":2106,"activeCount":8},[],{"trials":2108,"activeCount":8},[],{"trials":2110,"activeCount":8},[2111],{"nctId":2112,"briefTitle":2113,"status":60,"phases":2114,"primaryCompletion":2115,"completion":2115,"start":2116,"enrollment":1870,"conditions":2117,"interventions":2119},"NCT00006399","Effects of Estrogen on Memory in Post-Menopausal Women and Patients With Alzheimer's Disease",[38],"2004-03","1999-09",[2118],"Alzheimer Disease",[2103,2120,2121],"Estrogen","Progesterone",{"trials":2123,"activeCount":8},[],{"trials":2125,"activeCount":8},[],{"trials":2127,"activeCount":8},[],{"intervention":2121,"totalTrials":45,"cells":2129},{"EARLY_PHASE1":2130,"PHASE1":2132,"PHASE2":2134,"PHASE3":2140,"PHASE4":2142,"NA":2144},{"trials":2131,"activeCount":8},[],{"trials":2133,"activeCount":8},[],{"trials":2135,"activeCount":8},[2136],{"nctId":2112,"briefTitle":2113,"status":60,"phases":2137,"primaryCompletion":2115,"completion":2115,"start":2116,"enrollment":1870,"conditions":2138,"interventions":2139},[38],[2118],[2103,2120,2121],{"trials":2141,"activeCount":8},[],{"trials":2143,"activeCount":8},[],{"trials":2145,"activeCount":8},[],{"intervention":2147,"totalTrials":45,"cells":2148},"ribose",{"EARLY_PHASE1":2149,"PHASE1":2151,"PHASE2":2153,"PHASE3":2164,"PHASE4":2166,"NA":2168},{"trials":2150,"activeCount":8},[],{"trials":2152,"activeCount":8},[],{"trials":2154,"activeCount":8},[2155],{"nctId":2156,"briefTitle":2157,"status":60,"phases":2158,"start":1636,"conditions":2159,"interventions":2161},"NCT00004658","Phase II Study of Ribose, Uridine, and Thymidine for a Complex Syndrome Involving Excessive 5'-Nucleotidase Activity",[38],[2160],"5'-Nucleotidase Syndrome",[2147,2162,2163],"thymidine","uridine",{"trials":2165,"activeCount":8},[],{"trials":2167,"activeCount":8},[],{"trials":2169,"activeCount":8},[],{"intervention":2162,"totalTrials":45,"cells":2171},{"EARLY_PHASE1":2172,"PHASE1":2174,"PHASE2":2176,"PHASE3":2182,"PHASE4":2184,"NA":2186},{"trials":2173,"activeCount":8},[],{"trials":2175,"activeCount":8},[],{"trials":2177,"activeCount":8},[2178],{"nctId":2156,"briefTitle":2157,"status":60,"phases":2179,"start":1636,"conditions":2180,"interventions":2181},[38],[2160],[2147,2162,2163],{"trials":2183,"activeCount":8},[],{"trials":2185,"activeCount":8},[],{"trials":2187,"activeCount":8},[],{"intervention":2163,"totalTrials":45,"cells":2189},{"EARLY_PHASE1":2190,"PHASE1":2192,"PHASE2":2194,"PHASE3":2200,"PHASE4":2202,"NA":2204},{"trials":2191,"activeCount":8},[],{"trials":2193,"activeCount":8},[],{"trials":2195,"activeCount":8},[2196],{"nctId":2156,"briefTitle":2157,"status":60,"phases":2197,"start":1636,"conditions":2198,"interventions":2199},[38],[2160],[2147,2162,2163],{"trials":2201,"activeCount":8},[],{"trials":2203,"activeCount":8},[],{"trials":2205,"activeCount":8},[],{"intervention":2207,"totalTrials":45,"cells":2208},"pioglitazone",{"EARLY_PHASE1":2209,"PHASE1":2211,"PHASE2":2213,"PHASE3":2224,"PHASE4":2226,"NA":2228},{"trials":2210,"activeCount":8},[],{"trials":2212,"activeCount":8},[],{"trials":2214,"activeCount":8},[2215],{"nctId":2216,"briefTitle":2217,"status":60,"phases":2218,"enrollment":130,"conditions":2219,"interventions":2221},"NCT00015626","A Clinical Trial to Prevent the Complications of Insulin Resistance (Including Type-2 Diabetes)",[38],[2220,25],"Insulin Resistance",[2222,2207,2223],"Metformin","rosiglitazone",{"trials":2225,"activeCount":8},[],{"trials":2227,"activeCount":8},[],{"trials":2229,"activeCount":8},[],{"intervention":2231,"totalTrials":45,"cells":2232},"fluconazole",{"EARLY_PHASE1":2233,"PHASE1":2235,"PHASE2":2237,"PHASE3":2247,"PHASE4":2249,"NA":2251},{"trials":2234,"activeCount":8},[],{"trials":2236,"activeCount":8},[],{"trials":2238,"activeCount":8},[2239],{"nctId":2240,"briefTitle":2241,"status":60,"phases":2242,"start":2243,"enrollment":2244,"conditions":2245,"interventions":2246},"NCT00004808","Phase II Pilot Study of Fluconazole for Histoplasmosis, Blastomycosis, and Sporotrichosis",[38],"1991-09",78,[2068,2069,2070],[2231],{"trials":2248,"activeCount":8},[],{"trials":2250,"activeCount":8},[],{"trials":2252,"activeCount":8},[],{"intervention":2254,"totalTrials":45,"cells":2255},"NTBC",{"EARLY_PHASE1":2256,"PHASE1":2258,"PHASE2":2260,"PHASE3":2269,"PHASE4":2271,"NA":2273},{"trials":2257,"activeCount":8},[],{"trials":2259,"activeCount":8},[],{"trials":2261,"activeCount":8},[2262],{"nctId":2263,"briefTitle":2264,"status":60,"phases":2265,"start":1749,"conditions":2266,"interventions":2268},"NCT00004333","Phase II Study of the Enzyme Inhibitor NTBC for Tyrosinemia Type I",[38],[2267],"Tyrosinemia, Type I",[2254],{"trials":2270,"activeCount":8},[],{"trials":2272,"activeCount":8},[],{"trials":2274,"activeCount":8},[],{"intervention":2276,"totalTrials":45,"cells":2277},"-aminosalicylic acid",{"EARLY_PHASE1":2278,"PHASE1":2280,"PHASE2":2282,"PHASE3":2291,"PHASE4":2293,"NA":2295},{"trials":2279,"activeCount":8},[],{"trials":2281,"activeCount":8},[],{"trials":2283,"activeCount":8},[2284],{"nctId":2285,"briefTitle":2286,"status":60,"phases":2287,"start":1979,"enrollment":9,"conditions":2288,"interventions":2290},"NCT00004810","Phase II Placebo-Controlled Study of 4-Aminosalicylic Acid for Ulcerative Colitis",[38],[2289],"Ulcerative Colitis",[2276],{"trials":2292,"activeCount":8},[],{"trials":2294,"activeCount":8},[],{"trials":2296,"activeCount":8},[],{"intervention":1022,"totalTrials":45,"cells":2298},{"EARLY_PHASE1":2299,"PHASE1":2301,"PHASE2":2303,"PHASE3":2309,"PHASE4":2311,"NA":2313},{"trials":2300,"activeCount":8},[],{"trials":2302,"activeCount":8},[],{"trials":2304,"activeCount":8},[2305],{"nctId":1016,"briefTitle":1017,"status":167,"phases":2306,"conditions":2307,"interventions":2308},[38],[1020],[989,1022],{"trials":2310,"activeCount":8},[],{"trials":2312,"activeCount":8},[],{"trials":2314,"activeCount":8},[],{"intervention":2316,"totalTrials":45,"cells":2317},"methoxsalen",{"EARLY_PHASE1":2318,"PHASE1":2320,"PHASE2":2322,"PHASE3":2331,"PHASE4":2333,"NA":2335},{"trials":2319,"activeCount":8},[],{"trials":2321,"activeCount":8},[],{"trials":2323,"activeCount":8},[2324],{"nctId":2325,"briefTitle":2326,"status":60,"phases":2327,"start":291,"enrollment":354,"conditions":2328,"interventions":2330},"NCT00004359","Phase II Pilot Study of Extracorporeal Phototherapy for Epidermolysis Bullosa Acquisita",[38],[2329],"Epidermolysis Bullosa Acquisita",[2316],{"trials":2332,"activeCount":8},[],{"trials":2334,"activeCount":8},[],{"trials":2336,"activeCount":8},[],{"intervention":2338,"totalTrials":45,"cells":2339},"metoclopramide",{"EARLY_PHASE1":2340,"PHASE1":2342,"PHASE2":2344,"PHASE3":2353,"PHASE4":2355,"NA":2357},{"trials":2341,"activeCount":8},[],{"trials":2343,"activeCount":8},[],{"trials":2345,"activeCount":8},[2346],{"nctId":2347,"briefTitle":2348,"status":60,"phases":2349,"conditions":2350,"interventions":2352},"NCT00008736","Electrogastrography (EGC) in Premature Infants With Feeding Intolerance",[38],[2351],"Infant, Newborn, Diseases",[2338],{"trials":2354,"activeCount":8},[],{"trials":2356,"activeCount":8},[],{"trials":2358,"activeCount":8},[],{"intervention":2360,"totalTrials":45,"cells":2361},"recombinant-methionyl human glial cell line-derived neurotrophic factor",{"EARLY_PHASE1":2362,"PHASE1":2364,"PHASE2":2373,"PHASE3":2375,"PHASE4":2377,"NA":2379},{"trials":2363,"activeCount":8},[],{"trials":2365,"activeCount":8},[2366],{"nctId":2367,"briefTitle":2368,"status":60,"phases":2369,"conditions":2370,"interventions":2372},"NCT00006488","Continuously Infused Intracerebral (IC) Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (r-metHuGDNF) for the Treatment of Idiopathic Parkinson's Disease",[37],[2371],"Parkinson Disease",[2360],{"trials":2374,"activeCount":8},[],{"trials":2376,"activeCount":8},[],{"trials":2378,"activeCount":8},[],{"trials":2380,"activeCount":8},[],{"intervention":2382,"totalTrials":45,"cells":2383},"monoclonal antibody M-T412",{"EARLY_PHASE1":2384,"PHASE1":2386,"PHASE2":2394,"PHASE3":2396,"PHASE4":2398,"NA":2400},{"trials":2385,"activeCount":8},[],{"trials":2387,"activeCount":8},[2388],{"nctId":2389,"briefTitle":2390,"status":60,"phases":2391,"start":1276,"enrollment":150,"conditions":2392,"interventions":2393},"NCT00004816","A Maintenance Extension of Phase I Pilot Study of Chimeric Anti-CD4 Antibody M-T412 in Patients With Multiple Sclerosis",[37],[32],[2382],{"trials":2395,"activeCount":8},[],{"trials":2397,"activeCount":8},[],{"trials":2399,"activeCount":8},[],{"trials":2401,"activeCount":8},[],{"intervention":2403,"totalTrials":45,"cells":2404},"human glucocerebrosidase gene into autologous peripheral blood stem cells",{"EARLY_PHASE1":2405,"PHASE1":2407,"PHASE2":2415,"PHASE3":2417,"PHASE4":2419,"NA":2421},{"trials":2406,"activeCount":8},[],{"trials":2408,"activeCount":8},[2409],{"nctId":2410,"briefTitle":2411,"status":60,"phases":2412,"start":290,"enrollment":383,"conditions":2413,"interventions":2414},"NCT00004294","Phase I Study of Retrovirally Mediated Transfer of the Human Glucocerebrosidase Gene Into Peripheral Blood Stem Cells for Autologous Transplantation in Patients With Type I Gaucher Disease",[37],[2045],[2403],{"trials":2416,"activeCount":8},[],{"trials":2418,"activeCount":8},[],{"trials":2420,"activeCount":8},[],{"trials":2422,"activeCount":8},[],{"intervention":2424,"totalTrials":45,"cells":2425},"Ornithine transcarbamylase vector",{"EARLY_PHASE1":2426,"PHASE1":2428,"PHASE2":2436,"PHASE3":2438,"PHASE4":2440,"NA":2442},{"trials":2427,"activeCount":8},[],{"trials":2429,"activeCount":8},[2430],{"nctId":2431,"briefTitle":2432,"status":167,"phases":2433,"start":1340,"enrollment":161,"conditions":2434,"interventions":2435},"NCT00004307","Study of Treatment and Metabolism in Patients With Urea Cycle Disorders",[37],[1366],[2424],{"trials":2437,"activeCount":8},[],{"trials":2439,"activeCount":8},[],{"trials":2441,"activeCount":8},[],{"trials":2443,"activeCount":8},[],{"intervention":2445,"totalTrials":45,"cells":2446},"NNC 90-1170",{"EARLY_PHASE1":2447,"PHASE1":2449,"PHASE2":2458,"PHASE3":2460,"PHASE4":2462,"NA":2464},{"trials":2448,"activeCount":8},[],{"trials":2450,"activeCount":8},[2451],{"nctId":2452,"briefTitle":2453,"status":60,"phases":2454,"enrollment":9,"conditions":2455,"interventions":2457},"NCT00013910","NNC 90-1170 Mechanism of Action: A Double-Blind, Randomized, Single-Center, Placebo-Controlled, Crossover Study to Examine Beta-Cell Responsiveness to Graded Glucose Infusion in Subjects With Type 2 Diabetes",[37],[2456],"Diabetes Mellitus, Non-Insulin-Dependent",[2445],{"trials":2459,"activeCount":8},[],{"trials":2461,"activeCount":8},[],{"trials":2463,"activeCount":8},[],{"trials":2465,"activeCount":8},[],{"intervention":2467,"totalTrials":45,"cells":2468},"Ad5-CB-CFTR",{"EARLY_PHASE1":2469,"PHASE1":2471,"PHASE2":2480,"PHASE3":2482,"PHASE4":2484,"NA":2486},{"trials":2470,"activeCount":8},[],{"trials":2472,"activeCount":8},[2473],{"nctId":2474,"briefTitle":2475,"status":60,"phases":2476,"start":1869,"enrollment":2477,"conditions":2478,"interventions":2479},"NCT00004779","Phase I Pilot Study of Ad5-CB-CFTR, an Adenovirus Vector Containing the Cystic Fibrosis Transmembrane Conductance Regulator Gene, in Patients With Cystic Fibrosis",[37],12,[14],[2467],{"trials":2481,"activeCount":8},[],{"trials":2483,"activeCount":8},[],{"trials":2485,"activeCount":8},[],{"trials":2487,"activeCount":8},[],{"intervention":2489,"totalTrials":45,"cells":2490},"Autologous dendritic cells transfected with amplified tumor RNA",{"EARLY_PHASE1":2491,"PHASE1":2493,"PHASE2":2502,"PHASE3":2504,"PHASE4":2506,"NA":2508},{"trials":2492,"activeCount":8},[],{"trials":2494,"activeCount":8},[2495],{"nctId":2496,"briefTitle":2497,"status":167,"phases":2498,"conditions":2499,"interventions":2501},"NCT00006430","A Safety and Feasibility Study of Active Immunotherapy in Patients With Metastatic Prostate Carcinoma Using Autologous Dendritic Cells Pulsed With Antigen Encoded in Amplified Autologous Tumor RNA",[37],[2500],"Prostate Cancer",[2489],{"trials":2503,"activeCount":8},[],{"trials":2505,"activeCount":8},[],{"trials":2507,"activeCount":8},[],{"trials":2509,"activeCount":8},[],{"intervention":2511,"totalTrials":45,"cells":2512},"N-monomethyl-L-arginine",{"EARLY_PHASE1":2513,"PHASE1":2515,"PHASE2":2523,"PHASE3":2525,"PHASE4":2527,"NA":2529},{"trials":2514,"activeCount":8},[],{"trials":2516,"activeCount":8},[2517],{"nctId":2518,"briefTitle":2519,"status":167,"phases":2520,"conditions":2521,"interventions":2522},"NCT00005107","Role of Nitric Oxide in Cirrhosis: Relationship With Systemic Hemodynamics, Renal Function, Vasoactive Systems and Endotoxemia",[37],[385,386],[2511],{"trials":2524,"activeCount":8},[],{"trials":2526,"activeCount":8},[],{"trials":2528,"activeCount":8},[],{"trials":2530,"activeCount":8},[],{"intervention":2532,"totalTrials":45,"cells":2533},"von Willebrand factor",{"EARLY_PHASE1":2534,"PHASE1":2536,"PHASE2":2545,"PHASE3":2547,"PHASE4":2549,"NA":2551},{"trials":2535,"activeCount":8},[],{"trials":2537,"activeCount":8},[2538],{"nctId":2539,"briefTitle":2540,"status":60,"phases":2541,"start":129,"enrollment":354,"conditions":2542,"interventions":2544},"NCT00004667","Phase I Study of Human Von Willebrand Factor for Von Willebrand's Disease",[37],[2543],"Von Willebrand's Disease",[2532],{"trials":2546,"activeCount":8},[],{"trials":2548,"activeCount":8},[],{"trials":2550,"activeCount":8},[],{"trials":2552,"activeCount":8},[],{"intervention":2554,"totalTrials":45,"cells":2555},"R115777",{"EARLY_PHASE1":2556,"PHASE1":2558,"PHASE2":2568,"PHASE3":2570,"PHASE4":2572,"NA":2574},{"trials":2557,"activeCount":8},[],{"trials":2559,"activeCount":8},[2560],{"nctId":2561,"briefTitle":2562,"status":167,"phases":2563,"conditions":2564,"interventions":2566},"NCT00006199","Study of the Farnesyl Transferase Inhibitor, R115777, in Combination With Topotecan (NYU 99-32)",[37],[2565],"Cancer",[2554,2567],"Topotecan",{"trials":2569,"activeCount":8},[],{"trials":2571,"activeCount":8},[],{"trials":2573,"activeCount":8},[],{"trials":2575,"activeCount":8},[],{"intervention":2567,"totalTrials":45,"cells":2577},{"EARLY_PHASE1":2578,"PHASE1":2580,"PHASE2":2586,"PHASE3":2588,"PHASE4":2590,"NA":2592},{"trials":2579,"activeCount":8},[],{"trials":2581,"activeCount":8},[2582],{"nctId":2561,"briefTitle":2562,"status":167,"phases":2583,"conditions":2584,"interventions":2585},[37],[2565],[2554,2567],{"trials":2587,"activeCount":8},[],{"trials":2589,"activeCount":8},[],{"trials":2591,"activeCount":8},[],{"trials":2593,"activeCount":8},[],{"intervention":2595,"totalTrials":45,"cells":2596},"H5.001CBCFTR",{"EARLY_PHASE1":2597,"PHASE1":2599,"PHASE2":2608,"PHASE3":2610,"PHASE4":2612,"NA":2614},{"trials":2598,"activeCount":8},[],{"trials":2600,"activeCount":8},[2601],{"nctId":2602,"briefTitle":2603,"status":60,"phases":2604,"start":244,"enrollment":2605,"conditions":2606,"interventions":2607},"NCT00004287","Phase I Study of the Third Generation Adenovirus H5.001CBCFTR in Patients With Cystic Fibrosis",[37],14,[14],[2595],{"trials":2609,"activeCount":8},[],{"trials":2611,"activeCount":8},[],{"trials":2613,"activeCount":8},[],{"trials":2615,"activeCount":8},[],{"intervention":2617,"totalTrials":45,"cells":2618},"Carvedilol",{"EARLY_PHASE1":2619,"PHASE1":2621,"PHASE2":2630,"PHASE3":2632,"PHASE4":2634,"NA":2636},{"trials":2620,"activeCount":8},[],{"trials":2622,"activeCount":8},[2623],{"nctId":2624,"briefTitle":2625,"status":60,"phases":2626,"conditions":2627,"interventions":2629},"NCT00004854","The Safety and Efficacy of Adjunct Carvedilol in Children With Moderate Heart Failure",[37],[2628],"Heart Diseases",[2617],{"trials":2631,"activeCount":8},[],{"trials":2633,"activeCount":8},[],{"trials":2635,"activeCount":8},[],{"trials":2637,"activeCount":8},[],{"intervention":2639,"totalTrials":45,"cells":2640},"DC RCC-RNA",{"EARLY_PHASE1":2641,"PHASE1":2643,"PHASE2":2652,"PHASE3":2654,"PHASE4":2656,"NA":2658},{"trials":2642,"activeCount":8},[],{"trials":2644,"activeCount":8},[2645],{"nctId":2646,"briefTitle":2647,"status":167,"phases":2648,"conditions":2649,"interventions":2651},"NCT00006431","Active Immunotherapy Of Metastatic Renal Cell Carcinoma Using Autologous Dendritic Cells Transfected With Autologous Total Tumor RNA",[37],[2650],"Renal Cell Carcinoma",[2639],{"trials":2653,"activeCount":8},[],{"trials":2655,"activeCount":8},[],{"trials":2657,"activeCount":8},[],{"trials":2659,"activeCount":8},[],{"intervention":261,"totalTrials":33,"cells":2661},{"EARLY_PHASE1":2662,"PHASE1":2664,"PHASE2":2666,"PHASE3":2672,"PHASE4":2682,"NA":2684},{"trials":2663,"activeCount":8},[],{"trials":2665,"activeCount":8},[],{"trials":2667,"activeCount":8},[2668],{"nctId":351,"briefTitle":352,"status":60,"phases":2669,"start":149,"enrollment":354,"conditions":2670,"interventions":2671},[38],[356],[358,359,360,361,261,337],{"trials":2673,"activeCount":8},[2674,2678],{"nctId":252,"briefTitle":253,"status":60,"phases":2675,"start":255,"enrollment":256,"conditions":2676,"interventions":2677},[39],[258],[260,261,231],{"nctId":263,"briefTitle":264,"status":60,"phases":2679,"start":266,"enrollment":267,"conditions":2680,"interventions":2681},[39],[258],[261,231],{"trials":2683,"activeCount":8},[],{"trials":2685,"activeCount":8},[2686],{"nctId":2687,"briefTitle":2688,"status":60,"phases":2689,"conditions":2690,"interventions":2692},"NCT00035074","A Pharmacokinetic Study to Determine the Oral Bioavailability of Methotrexate in Patients With Inflammatory Bowel Disease",[41],[2691],"Inflammatory Bowel Disease",[2693],"Methotrexate",{"intervention":2695,"totalTrials":232,"cells":2696},"metformin",{"EARLY_PHASE1":2697,"PHASE1":2699,"PHASE2":2701,"PHASE3":2707,"PHASE4":2709,"NA":2711},{"trials":2698,"activeCount":8},[],{"trials":2700,"activeCount":8},[],{"trials":2702,"activeCount":8},[2703],{"nctId":2216,"briefTitle":2217,"status":60,"phases":2704,"enrollment":130,"conditions":2705,"interventions":2706},[38],[2220,25],[2222,2207,2223],{"trials":2708,"activeCount":8},[],{"trials":2710,"activeCount":8},[],{"trials":2712,"activeCount":8},[2713,2722],{"nctId":2714,"briefTitle":2715,"status":60,"phases":2716,"start":1613,"enrollment":2717,"conditions":2718,"interventions":2720},"NCT00005654","Randomized Study of the Effect of Decreased Hyperinsulinemia on the Ovulatory Response to Clomiphene Citrate in Obese Women With Polycystic Ovary Syndrome",[41],88,[2719,2004],"Hyperinsulinism",[2721,2695],"clomiphene citrate",{"nctId":2723,"briefTitle":2724,"status":60,"phases":2725,"start":1613,"enrollment":2726,"conditions":2727,"interventions":2728},"NCT00005104","Randomized Study of Decreased Hyperinsulinemia on the Ovulatory Response to Clomiphene Citrate in Women With Polycystic Ovary Syndrome",[41],99,[2004,2719],[2721,2695],{"intervention":2730,"totalTrials":232,"cells":2731},"growth hormone",{"EARLY_PHASE1":2732,"PHASE1":2734,"PHASE2":2736,"PHASE3":2748,"PHASE4":2750,"NA":2752},{"trials":2733,"activeCount":8},[],{"trials":2735,"activeCount":8},[],{"trials":2737,"activeCount":8},[2738],{"nctId":2739,"briefTitle":2740,"status":60,"phases":2741,"start":196,"enrollment":2742,"conditions":2743,"interventions":2746},"NCT00004340","Phase II Randomized Study of the Effects of Growth Hormone on Children and Adolescents on Maintenance Dialysis",[38],109,[2744,2745],"Renal Osteodystrophy","End Stage Renal Disease",[2747,2730],"calcitriol",{"trials":2749,"activeCount":8},[],{"trials":2751,"activeCount":8},[],{"trials":2753,"activeCount":8},[2754,2762],{"nctId":2755,"briefTitle":2756,"status":60,"phases":2757,"start":2758,"enrollment":45,"conditions":2759,"interventions":2761},"NCT00004815","Descriptive Study of Recombinant Human Insulin-Like Growth Factor for Osteoporosis in Werner's Syndrome",[41],"1992-05",[2760],"Werner's Syndrome",[2730],{"nctId":2763,"briefTitle":2764,"status":60,"phases":2765,"start":2766,"enrollment":2767,"conditions":2768,"interventions":2770},"NCT00006394","Randomized Study of Growth Hormone on Bone Mineral Density in Patients With Adult Onset Growth Hormone Deficiency",[41],"1997-04",72,[30,2769],"Growth Hormone Deficiency",[2730],{"intervention":2223,"totalTrials":232,"cells":2772},{"EARLY_PHASE1":2773,"PHASE1":2775,"PHASE2":2777,"PHASE3":2791,"PHASE4":2793,"NA":2795},{"trials":2774,"activeCount":8},[],{"trials":2776,"activeCount":8},[],{"trials":2778,"activeCount":8},[2779,2787],{"nctId":2780,"briefTitle":2781,"status":60,"phases":2782,"conditions":2783,"interventions":2785},"NCT00006493","Rosiglitazone in the Treatment of HIV-Associated Hyperlipidemia",[38],[20,2784],"Hyperlipidemia",[2786],"Rosiglitazone",{"nctId":2216,"briefTitle":2217,"status":60,"phases":2788,"enrollment":130,"conditions":2789,"interventions":2790},[38],[2220,25],[2222,2207,2223],{"trials":2792,"activeCount":8},[],{"trials":2794,"activeCount":8},[],{"trials":2796,"activeCount":8},[2797],{"nctId":2798,"briefTitle":2799,"status":60,"phases":2800,"conditions":2801,"interventions":2802},"NCT00025753","Rosiglitazone and Exercise Training: Effects on HIV-Infected People With Insulin Resistance, Hypertriglyceridemia, and Adipose Tissue Maldistribution",[41],[20,2220],[2223],{"intervention":2120,"totalTrials":232,"cells":2804},{"EARLY_PHASE1":2805,"PHASE1":2807,"PHASE2":2809,"PHASE3":2821,"PHASE4":2823,"NA":2825},{"trials":2806,"activeCount":8},[],{"trials":2808,"activeCount":8},[],{"trials":2810,"activeCount":8},[2811,2817],{"nctId":2812,"briefTitle":2813,"status":167,"phases":2814,"conditions":2815,"interventions":2816},"NCT00005768","Estrogen Modulation of Mood and Cognition Following Monoaminergic Depletion in Post-Menopausal Women",[38],[1528],[2120],{"nctId":2112,"briefTitle":2113,"status":60,"phases":2818,"primaryCompletion":2115,"completion":2115,"start":2116,"enrollment":1870,"conditions":2819,"interventions":2820},[38],[2118],[2103,2120,2121],{"trials":2822,"activeCount":8},[],{"trials":2824,"activeCount":8},[],{"trials":2826,"activeCount":8},[2827],{"nctId":2828,"briefTitle":2829,"status":60,"phases":2830,"enrollment":383,"conditions":2831,"interventions":2833},"NCT00029757","Buccal Estrogen in Toothpaste Study: Systemic Absorption of Estradiol When Administered Mixed With Toothpaste in Postmenopausal or Surgically Menopausal Women",[41],[1528,2832],"Postmenopause",[2120],{"intervention":2835,"totalTrials":232,"cells":2836},"testosterone",{"EARLY_PHASE1":2837,"PHASE1":2839,"PHASE2":2841,"PHASE3":2852,"PHASE4":2854,"NA":2856},{"trials":2838,"activeCount":8},[],{"trials":2840,"activeCount":8},[],{"trials":2842,"activeCount":8},[2843],{"nctId":2844,"briefTitle":2845,"status":60,"phases":2846,"start":2847,"enrollment":207,"conditions":2848,"interventions":2851},"NCT00004771","Phase II Study of Leuprolide and Testosterone for Men With Kennedy's Disease or Other Motor Neuron Disease",[38],"1992-10",[2849,1188,2850],"Spinal Muscular Atrophy","Spinobulbar Muscular Atrophy",[1874,2835],{"trials":2853,"activeCount":8},[],{"trials":2855,"activeCount":8},[],{"trials":2857,"activeCount":8},[2858,2865],{"nctId":2859,"briefTitle":2860,"status":167,"phases":2861,"start":711,"enrollment":645,"conditions":2862,"interventions":2864},"NCT00006129","Randomized Study of Testosterone and Progressive Resistance Exercise in Men With Burn Injury",[41],[2863],"Burns",[2835],{"nctId":2866,"briefTitle":2867,"status":60,"phases":2868,"start":2869,"enrollment":33,"conditions":2870,"interventions":2872},"NCT00004344","Purification of Testis-Stimulating Factor in Precocious Puberty",[],"1997-01",[2871],"Precocious Puberty",[1874,2835],{"intervention":1874,"totalTrials":232,"cells":2874},{"EARLY_PHASE1":2875,"PHASE1":2877,"PHASE2":2879,"PHASE3":2889,"PHASE4":2891,"NA":2893},{"trials":2876,"activeCount":8},[],{"trials":2878,"activeCount":8},[],{"trials":2880,"activeCount":8},[2881,2885],{"nctId":1866,"briefTitle":1867,"status":60,"phases":2882,"start":1869,"enrollment":1870,"conditions":2883,"interventions":2884},[38],[1872],[1874,1857],{"nctId":2844,"briefTitle":2845,"status":60,"phases":2886,"start":2847,"enrollment":207,"conditions":2887,"interventions":2888},[38],[2849,1188,2850],[1874,2835],{"trials":2890,"activeCount":8},[],{"trials":2892,"activeCount":8},[],{"trials":2894,"activeCount":8},[2895],{"nctId":2866,"briefTitle":2867,"status":60,"phases":2896,"start":2869,"enrollment":33,"conditions":2897,"interventions":2898},[],[2871],[1874,2835],{"intervention":2900,"totalTrials":276,"cells":2901},"Vitamin D",{"EARLY_PHASE1":2902,"PHASE1":2904,"PHASE2":2912,"PHASE3":2914,"PHASE4":2916,"NA":2918},{"trials":2903,"activeCount":8},[],{"trials":2905,"activeCount":8},[2906],{"nctId":2907,"briefTitle":2908,"status":60,"phases":2909,"conditions":2910,"interventions":2911},"NCT00006196","The Relationship Between Vitamin D, Fingernail Thickness and Bone Density",[37],[30],[2900],{"trials":2913,"activeCount":8},[],{"trials":2915,"activeCount":8},[],{"trials":2917,"activeCount":8},[],{"trials":2919,"activeCount":8},[2920],{"nctId":2921,"briefTitle":2922,"status":60,"phases":2923,"conditions":2924,"interventions":2926},"NCT00013962","Vitamin D Metabolism and the Williams Syndrome",[],[2925],"Williams Syndrome",[2900],{"intervention":2721,"totalTrials":276,"cells":2928},{"EARLY_PHASE1":2929,"PHASE1":2931,"PHASE2":2933,"PHASE3":2935,"PHASE4":2937,"NA":2939},{"trials":2930,"activeCount":8},[],{"trials":2932,"activeCount":8},[],{"trials":2934,"activeCount":8},[],{"trials":2936,"activeCount":8},[],{"trials":2938,"activeCount":8},[],{"trials":2940,"activeCount":8},[2941,2945],{"nctId":2714,"briefTitle":2715,"status":60,"phases":2942,"start":1613,"enrollment":2717,"conditions":2943,"interventions":2944},[41],[2719,2004],[2721,2695],{"nctId":2723,"briefTitle":2724,"status":60,"phases":2946,"start":1613,"enrollment":2726,"conditions":2947,"interventions":2948},[41],[2004,2719],[2721,2695],{"intervention":2950,"totalTrials":276,"cells":2951},"ganciclovir",{"EARLY_PHASE1":2952,"PHASE1":2954,"PHASE2":2956,"PHASE3":2958,"PHASE4":2967,"NA":2969},{"trials":2953,"activeCount":8},[],{"trials":2955,"activeCount":8},[],{"trials":2957,"activeCount":8},[],{"trials":2959,"activeCount":8},[2960],{"nctId":2961,"briefTitle":2962,"status":60,"phases":2963,"start":1661,"enrollment":2964,"conditions":2965,"interventions":2966},"NCT00004278","Phase III Randomized, Controlled Study of Ganciclovir for Symptomatic Congenital Cytomegalovirus Infection",[39],130,[1550],[2950],{"trials":2968,"activeCount":8},[],{"trials":2970,"activeCount":8},[2971],{"nctId":2972,"briefTitle":2973,"status":167,"phases":2974,"conditions":2975,"interventions":2976},"NCT00004573","Kinetics of Response of Cytomegalovirus With Ganciclovir Treatment Using Quantitative Real-Time PCR",[41],[1550],[2950],{"intervention":2978,"totalTrials":276,"cells":2979},"risperidone",{"EARLY_PHASE1":2980,"PHASE1":2982,"PHASE2":2984,"PHASE3":2994,"PHASE4":2996,"NA":2998},{"trials":2981,"activeCount":8},[],{"trials":2983,"activeCount":8},[],{"trials":2985,"activeCount":8},[2986],{"nctId":2987,"briefTitle":2988,"status":60,"phases":2989,"completion":2990,"start":2991,"enrollment":1010,"conditions":2992,"interventions":2993},"NCT00004393","Phase II Double Blind Placebo Controlled Trial of Risperidone in Tourette Syndrome",[38],"2000-09","1997-07",[27],[2978],{"trials":2995,"activeCount":8},[],{"trials":2997,"activeCount":8},[],{"trials":2999,"activeCount":8},[3000],{"nctId":3001,"briefTitle":3002,"status":167,"phases":3003,"conditions":3004,"interventions":3006},"NCT00006195","Glucose Regulation During Risperidone and Olanzapine Treatment",[41],[3005],"Schizophrenia",[2978,3007],"olanzapine",{"intervention":1450,"totalTrials":276,"cells":3009},{"EARLY_PHASE1":3010,"PHASE1":3012,"PHASE2":3014,"PHASE3":3020,"PHASE4":3022,"NA":3024},{"trials":3011,"activeCount":8},[],{"trials":3013,"activeCount":8},[],{"trials":3015,"activeCount":8},[3016],{"nctId":1444,"briefTitle":1445,"status":60,"phases":3017,"start":753,"enrollment":9,"conditions":3018,"interventions":3019},[38],[1448,108],[1435,1450,1451,1452,1453],{"trials":3021,"activeCount":8},[],{"trials":3023,"activeCount":8},[],{"trials":3025,"activeCount":8},[3026],{"nctId":3027,"briefTitle":3028,"status":60,"phases":3029,"start":223,"enrollment":3030,"conditions":3031,"interventions":3033},"NCT00005890","Diagnostic Study of Adrenal Cortical Function in Children With Septic Shock",[41],56,[3032],"Septic Shock",[1450],{"intervention":2095,"totalTrials":276,"cells":3035},{"EARLY_PHASE1":3036,"PHASE1":3038,"PHASE2":3040,"PHASE3":3046,"PHASE4":3048,"NA":3050},{"trials":3037,"activeCount":8},[],{"trials":3039,"activeCount":8},[],{"trials":3041,"activeCount":8},[3042],{"nctId":2088,"briefTitle":2089,"status":60,"phases":3043,"start":2091,"enrollment":45,"conditions":3044,"interventions":3045},[38],[2093],[2095,2079],{"trials":3047,"activeCount":8},[],{"trials":3049,"activeCount":8},[],{"trials":3051,"activeCount":8},[3052],{"nctId":3053,"briefTitle":3054,"status":60,"phases":3055,"start":922,"enrollment":3056,"conditions":3057,"interventions":3059},"NCT00006137","Pilot Study of Enalapril and Renal Function in Patients With IgA Nephropathy",[41],43,[3058],"IGA Glomerulonephritis",[2095],{"intervention":3061,"totalTrials":276,"cells":3062},"desmopressin",{"EARLY_PHASE1":3063,"PHASE1":3065,"PHASE2":3067,"PHASE3":3069,"PHASE4":3071,"NA":3073},{"trials":3064,"activeCount":8},[],{"trials":3066,"activeCount":8},[],{"trials":3068,"activeCount":8},[],{"trials":3070,"activeCount":8},[],{"trials":3072,"activeCount":8},[],{"trials":3074,"activeCount":8},[3075,3084],{"nctId":3076,"briefTitle":3077,"status":60,"phases":3078,"start":776,"conditions":3079,"interventions":3082},"NCT00004363","Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus",[],[3080,3081],"Diabetes Insipidus","Diabetes Insipidus, Neurohypophyseal",[3083,3061],"chlorpropamide",{"nctId":3085,"briefTitle":3086,"status":167,"phases":3087,"start":776,"enrollment":28,"conditions":3088,"interventions":3089},"NCT00004364","Study of Novel Types of Familial Diabetes Insipidus",[],[3080],[3061],{"intervention":3091,"totalTrials":276,"cells":3092},"glucose",{"EARLY_PHASE1":3093,"PHASE1":3095,"PHASE2":3097,"PHASE3":3099,"PHASE4":3101,"NA":3103},{"trials":3094,"activeCount":8},[],{"trials":3096,"activeCount":8},[],{"trials":3098,"activeCount":8},[],{"trials":3100,"activeCount":8},[],{"trials":3102,"activeCount":8},[],{"trials":3104,"activeCount":8},[3105,3116],{"nctId":3106,"briefTitle":3107,"status":3108,"phases":3109,"start":3110,"enrollment":3111,"conditions":3112,"interventions":3113},"NCT00014768","Study of Metabolic Effects of Pregnancy in Women With Cystic Fibrosis","TERMINATED",[],"2001-02",36,[14],[3091,3114,3115],"insulin","leucine",{"nctId":3117,"briefTitle":3118,"status":167,"phases":3119,"start":1090,"enrollment":3120,"conditions":3121,"interventions":3124},"NCT00005889","Gluconeogenesis in Very Low Birth Weight Infants Who Are Receiving Nutrition By Intravenous Infusion",[41],96,[3122,3123],"Infant, Low Birth Weight","Hyperglycemia",[3125,3126,3127,3091,883,3128,3114,3115,3129,3130],"alanine","amino acids","glucagon","glycerol","lipids","urea",{"intervention":3114,"totalTrials":276,"cells":3132},{"EARLY_PHASE1":3133,"PHASE1":3135,"PHASE2":3137,"PHASE3":3139,"PHASE4":3141,"NA":3143},{"trials":3134,"activeCount":8},[],{"trials":3136,"activeCount":8},[],{"trials":3138,"activeCount":8},[],{"trials":3140,"activeCount":8},[],{"trials":3142,"activeCount":8},[],{"trials":3144,"activeCount":8},[3145,3149],{"nctId":3106,"briefTitle":3107,"status":3108,"phases":3146,"start":3110,"enrollment":3111,"conditions":3147,"interventions":3148},[],[14],[3091,3114,3115],{"nctId":3117,"briefTitle":3118,"status":167,"phases":3150,"start":1090,"enrollment":3120,"conditions":3151,"interventions":3152},[41],[3122,3123],[3125,3126,3127,3091,883,3128,3114,3115,3129,3130],{"intervention":3115,"totalTrials":276,"cells":3154},{"EARLY_PHASE1":3155,"PHASE1":3157,"PHASE2":3159,"PHASE3":3161,"PHASE4":3163,"NA":3165},{"trials":3156,"activeCount":8},[],{"trials":3158,"activeCount":8},[],{"trials":3160,"activeCount":8},[],{"trials":3162,"activeCount":8},[],{"trials":3164,"activeCount":8},[],{"trials":3166,"activeCount":8},[3167,3171],{"nctId":3106,"briefTitle":3107,"status":3108,"phases":3168,"start":3110,"enrollment":3111,"conditions":3169,"interventions":3170},[],[14],[3091,3114,3115],{"nctId":3117,"briefTitle":3118,"status":167,"phases":3172,"start":1090,"enrollment":3120,"conditions":3173,"interventions":3174},[41],[3122,3123],[3125,3126,3127,3091,883,3128,3114,3115,3129,3130],{"intervention":2747,"totalTrials":276,"cells":3176},{"EARLY_PHASE1":3177,"PHASE1":3179,"PHASE2":3181,"PHASE3":3187,"PHASE4":3189,"NA":3191},{"trials":3178,"activeCount":8},[],{"trials":3180,"activeCount":8},[],{"trials":3182,"activeCount":8},[3183],{"nctId":2739,"briefTitle":2740,"status":60,"phases":3184,"start":196,"enrollment":2742,"conditions":3185,"interventions":3186},[38],[2744,2745],[2747,2730],{"trials":3188,"activeCount":8},[],{"trials":3190,"activeCount":8},[],{"trials":3192,"activeCount":8},[3193],{"nctId":3194,"briefTitle":3195,"status":60,"phases":3196,"completion":3197,"start":3197,"enrollment":197,"conditions":3198,"interventions":3200},"NCT00006275","Study of Topical Calcitriol in Children With Psoriasis",[41],"2000-07",[3199],"Psoriasis",[2747],{"intervention":883,"totalTrials":276,"cells":3202},{"EARLY_PHASE1":3203,"PHASE1":3205,"PHASE2":3207,"PHASE3":3209,"PHASE4":3215,"NA":3217},{"trials":3204,"activeCount":8},[],{"trials":3206,"activeCount":8},[],{"trials":3208,"activeCount":8},[],{"trials":3210,"activeCount":8},[3211],{"nctId":877,"briefTitle":878,"status":60,"phases":3212,"conditions":3213,"interventions":3214},[39],[881],[883,866],{"trials":3216,"activeCount":8},[],{"trials":3218,"activeCount":8},[3219],{"nctId":3117,"briefTitle":3118,"status":167,"phases":3220,"start":1090,"enrollment":3120,"conditions":3221,"interventions":3222},[41],[3122,3123],[3125,3126,3127,3091,883,3128,3114,3115,3129,3130],{"intervention":3224,"totalTrials":45,"cells":3225},"megestrol",{"EARLY_PHASE1":3226,"PHASE1":3228,"PHASE2":3230,"PHASE3":3232,"PHASE4":3234,"NA":3236},{"trials":3227,"activeCount":8},[],{"trials":3229,"activeCount":8},[],{"trials":3231,"activeCount":8},[],{"trials":3233,"activeCount":8},[],{"trials":3235,"activeCount":8},[],{"trials":3237,"activeCount":8},[3238],{"nctId":3239,"briefTitle":3240,"status":60,"phases":3241,"start":196,"enrollment":3242,"conditions":3243,"interventions":3245},"NCT00004664","Randomized Placebo-Controlled Study of Aerobic Exercise and Resistance Training Plus Megestrol Acetate for HIV-Wasting",[41],69,[1639,3244,20],"HIV Wasting Syndrome",[3224],{"intervention":3247,"totalTrials":45,"cells":3248},"magnesium gluconate",{"EARLY_PHASE1":3249,"PHASE1":3251,"PHASE2":3253,"PHASE3":3255,"PHASE4":3257,"NA":3259},{"trials":3250,"activeCount":8},[],{"trials":3252,"activeCount":8},[],{"trials":3254,"activeCount":8},[],{"trials":3256,"activeCount":8},[],{"trials":3258,"activeCount":8},[],{"trials":3260,"activeCount":8},[3261],{"nctId":3262,"briefTitle":3263,"status":60,"phases":3264,"start":3265,"enrollment":150,"conditions":3266,"interventions":3269},"NCT00007033","Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Disease",[41],"2000-10",[3267,247,3268],"Alagille Syndrome","Biliary Atresia",[3247,3270],"magnesium sulfate",{"intervention":3270,"totalTrials":45,"cells":3272},{"EARLY_PHASE1":3273,"PHASE1":3275,"PHASE2":3277,"PHASE3":3279,"PHASE4":3281,"NA":3283},{"trials":3274,"activeCount":8},[],{"trials":3276,"activeCount":8},[],{"trials":3278,"activeCount":8},[],{"trials":3280,"activeCount":8},[],{"trials":3282,"activeCount":8},[],{"trials":3284,"activeCount":8},[3285],{"nctId":3262,"briefTitle":3263,"status":60,"phases":3286,"start":3265,"enrollment":150,"conditions":3287,"interventions":3288},[41],[3267,247,3268],[3247,3270],{"intervention":3290,"totalTrials":45,"cells":3291},"pancrelipase with bicarbonate",{"EARLY_PHASE1":3292,"PHASE1":3294,"PHASE2":3296,"PHASE3":3298,"PHASE4":3300,"NA":3302},{"trials":3293,"activeCount":8},[],{"trials":3295,"activeCount":8},[],{"trials":3297,"activeCount":8},[],{"trials":3299,"activeCount":8},[],{"trials":3301,"activeCount":8},[],{"trials":3303,"activeCount":8},[3304],{"nctId":3305,"briefTitle":3306,"status":60,"phases":3307,"completion":3308,"start":3309,"enrollment":924,"conditions":3310,"interventions":3311},"NCT00006063","Randomized Study of Pancrelipase With Bicarbonate (PANCRECARB) Capsules in Reducing Steatorrhea in Patients With Cystic Fibrosis",[41],"1999-08","1999-07",[14],[3290],{"intervention":3313,"totalTrials":45,"cells":3314},"nicotine",{"EARLY_PHASE1":3315,"PHASE1":3317,"PHASE2":3319,"PHASE3":3321,"PHASE4":3323,"NA":3325},{"trials":3316,"activeCount":8},[],{"trials":3318,"activeCount":8},[],{"trials":3320,"activeCount":8},[],{"trials":3322,"activeCount":8},[],{"trials":3324,"activeCount":8},[],{"trials":3326,"activeCount":8},[3327],{"nctId":3328,"briefTitle":3329,"status":60,"phases":3330,"conditions":3331,"interventions":3333},"NCT00005765","Behavioral Economics of Human Drug Self-Administration",[],[3332],"Drug Dependence",[3313,3334],"alcohol",{"intervention":3334,"totalTrials":45,"cells":3336},{"EARLY_PHASE1":3337,"PHASE1":3339,"PHASE2":3341,"PHASE3":3343,"PHASE4":3345,"NA":3347},{"trials":3338,"activeCount":8},[],{"trials":3340,"activeCount":8},[],{"trials":3342,"activeCount":8},[],{"trials":3344,"activeCount":8},[],{"trials":3346,"activeCount":8},[],{"trials":3348,"activeCount":8},[3349],{"nctId":3328,"briefTitle":3329,"status":60,"phases":3350,"conditions":3351,"interventions":3352},[],[3332],[3313,3334],{"intervention":3354,"totalTrials":45,"cells":3355},"Valacyclovir",{"EARLY_PHASE1":3356,"PHASE1":3358,"PHASE2":3360,"PHASE3":3362,"PHASE4":3364,"NA":3366},{"trials":3357,"activeCount":8},[],{"trials":3359,"activeCount":8},[],{"trials":3361,"activeCount":8},[],{"trials":3363,"activeCount":8},[],{"trials":3365,"activeCount":8},[],{"trials":3367,"activeCount":8},[3368],{"nctId":3369,"briefTitle":3370,"status":60,"phases":3371,"start":2869,"enrollment":161,"conditions":3372,"interventions":3374},"NCT00006131","Randomized Study of Two Doses of Oral Valacyclovir in Immunocompromised Patients With Uncomplicated Herpes Zoster",[41],[802,3373],"Immunologic Deficiency Syndromes",[3354],{"intervention":3376,"totalTrials":45,"cells":3377},"Antiretroviral therapy",{"EARLY_PHASE1":3378,"PHASE1":3380,"PHASE2":3382,"PHASE3":3384,"PHASE4":3386,"NA":3388},{"trials":3379,"activeCount":8},[],{"trials":3381,"activeCount":8},[],{"trials":3383,"activeCount":8},[],{"trials":3385,"activeCount":8},[],{"trials":3387,"activeCount":8},[],{"trials":3389,"activeCount":8},[3390],{"nctId":3391,"briefTitle":3392,"status":60,"phases":3393,"conditions":3394,"interventions":3395},"NCT00004739","The Metabolic Effects of Protease Inhibitors in HIV Infected Children",[41],[20],[3376],{"intervention":3397,"totalTrials":45,"cells":3398},"pravastatin",{"EARLY_PHASE1":3399,"PHASE1":3401,"PHASE2":3403,"PHASE3":3405,"PHASE4":3407,"NA":3409},{"trials":3400,"activeCount":8},[],{"trials":3402,"activeCount":8},[],{"trials":3404,"activeCount":8},[],{"trials":3406,"activeCount":8},[],{"trials":3408,"activeCount":8},[],{"trials":3410,"activeCount":8},[3411],{"nctId":3412,"briefTitle":3413,"status":167,"phases":3414,"conditions":3415,"interventions":3416},"NCT00005117","Effect of Pravastatin on Endothelial Dysfunction Following a Single High Fat Meal",[41],[2628],[3397],{"intervention":3007,"totalTrials":45,"cells":3418},{"EARLY_PHASE1":3419,"PHASE1":3421,"PHASE2":3423,"PHASE3":3425,"PHASE4":3427,"NA":3429},{"trials":3420,"activeCount":8},[],{"trials":3422,"activeCount":8},[],{"trials":3424,"activeCount":8},[],{"trials":3426,"activeCount":8},[],{"trials":3428,"activeCount":8},[],{"trials":3430,"activeCount":8},[3431],{"nctId":3001,"briefTitle":3002,"status":167,"phases":3432,"conditions":3433,"interventions":3434},[41],[3005],[2978,3007],{"intervention":3436,"totalTrials":45,"cells":3437},"Oral lactobacillus administration",{"EARLY_PHASE1":3438,"PHASE1":3440,"PHASE2":3442,"PHASE3":3444,"PHASE4":3446,"NA":3448},{"trials":3439,"activeCount":8},[],{"trials":3441,"activeCount":8},[],{"trials":3443,"activeCount":8},[],{"trials":3445,"activeCount":8},[],{"trials":3447,"activeCount":8},[],{"trials":3449,"activeCount":8},[3450],{"nctId":3451,"briefTitle":3452,"status":60,"phases":3453,"conditions":3454,"interventions":3455},"NCT00011141","Lactobacillus Plantarum as Therapy for NK-T Cell Deficiency",[41],[25],[3436],{"intervention":3457,"totalTrials":45,"cells":3458},"dietary fat",{"EARLY_PHASE1":3459,"PHASE1":3461,"PHASE2":3463,"PHASE3":3465,"PHASE4":3467,"NA":3469},{"trials":3460,"activeCount":8},[],{"trials":3462,"activeCount":8},[],{"trials":3464,"activeCount":8},[],{"trials":3466,"activeCount":8},[],{"trials":3468,"activeCount":8},[],{"trials":3470,"activeCount":8},[3471],{"nctId":3472,"briefTitle":3473,"status":60,"phases":3474,"conditions":3475,"interventions":3477},"NCT00000110","Influence of Diet and Endurance Running on Intramuscular Lipids Measured at 4.1 TESLA",[41],[3476],"Obesity",[3457],{"intervention":3479,"totalTrials":45,"cells":3480},"Salmeterol",{"EARLY_PHASE1":3481,"PHASE1":3483,"PHASE2":3485,"PHASE3":3487,"PHASE4":3489,"NA":3491},{"trials":3482,"activeCount":8},[],{"trials":3484,"activeCount":8},[],{"trials":3486,"activeCount":8},[],{"trials":3488,"activeCount":8},[],{"trials":3490,"activeCount":8},[],{"trials":3492,"activeCount":8},[3493],{"nctId":3494,"briefTitle":3495,"status":3496,"phases":3497,"conditions":3498,"interventions":3499},"NCT00005110","A Multi-Centered Study of the Long-Term Effect of Salmeterol and Albuterol in Cystic Fibrosis","SUSPENDED",[41],[14],[3479,3500],"Albuterol",{"intervention":3500,"totalTrials":45,"cells":3502},{"EARLY_PHASE1":3503,"PHASE1":3505,"PHASE2":3507,"PHASE3":3509,"PHASE4":3511,"NA":3513},{"trials":3504,"activeCount":8},[],{"trials":3506,"activeCount":8},[],{"trials":3508,"activeCount":8},[],{"trials":3510,"activeCount":8},[],{"trials":3512,"activeCount":8},[],{"trials":3514,"activeCount":8},[3515],{"nctId":3494,"briefTitle":3495,"status":3496,"phases":3516,"conditions":3517,"interventions":3518},[41],[14],[3479,3500],{"intervention":3520,"totalTrials":45,"cells":3521},"Corticosteroids",{"EARLY_PHASE1":3522,"PHASE1":3524,"PHASE2":3526,"PHASE3":3528,"PHASE4":3530,"NA":3532},{"trials":3523,"activeCount":8},[],{"trials":3525,"activeCount":8},[],{"trials":3527,"activeCount":8},[],{"trials":3529,"activeCount":8},[],{"trials":3531,"activeCount":8},[],{"trials":3533,"activeCount":8},[3534],{"nctId":3535,"briefTitle":3536,"status":167,"phases":3537,"conditions":3538,"interventions":3540},"NCT00032526","Classical Conditioning to Treat Allergic Airway Diseases",[41],[3539],"Allergic Airway Disease",[3520],{"intervention":3083,"totalTrials":45,"cells":3542},{"EARLY_PHASE1":3543,"PHASE1":3545,"PHASE2":3547,"PHASE3":3549,"PHASE4":3551,"NA":3553},{"trials":3544,"activeCount":8},[],{"trials":3546,"activeCount":8},[],{"trials":3548,"activeCount":8},[],{"trials":3550,"activeCount":8},[],{"trials":3552,"activeCount":8},[],{"trials":3554,"activeCount":8},[3555],{"nctId":3076,"briefTitle":3077,"status":60,"phases":3556,"start":776,"conditions":3557,"interventions":3558},[],[3080,3081],[3083,3061],{"intervention":3560,"totalTrials":45,"cells":3561},"chlorothiazide",{"EARLY_PHASE1":3562,"PHASE1":3564,"PHASE2":3566,"PHASE3":3568,"PHASE4":3570,"NA":3572},{"trials":3563,"activeCount":8},[],{"trials":3565,"activeCount":8},[],{"trials":3567,"activeCount":8},[],{"trials":3569,"activeCount":8},[],{"trials":3571,"activeCount":8},[],{"trials":3573,"activeCount":8},[3574],{"nctId":3575,"briefTitle":3576,"status":60,"phases":3577,"start":3578,"conditions":3579,"interventions":3581},"NCT00004360","Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes Insipidus",[],"1995-09",[3580],"Diabetes Insipidus, Nephrogenic",[3560],{"intervention":3583,"totalTrials":45,"cells":3584},"luteinizing hormone-releasing factor",{"EARLY_PHASE1":3585,"PHASE1":3587,"PHASE2":3589,"PHASE3":3591,"PHASE4":3593,"NA":3595},{"trials":3586,"activeCount":8},[],{"trials":3588,"activeCount":8},[],{"trials":3590,"activeCount":8},[],{"trials":3592,"activeCount":8},[],{"trials":3594,"activeCount":8},[],{"trials":3596,"activeCount":8},[3597],{"nctId":3598,"briefTitle":3599,"status":60,"phases":3600,"start":3601,"conditions":3602,"interventions":3603},"NCT00004330","Studies in Porphyria IV: Gonadotropin-Releasing Hormone (GnRH) Analogues for Prevention of Cyclic Attacks",[41],"1987-03",[23],[3583],{"intervention":3605,"totalTrials":45,"cells":3606},"mycophenolate mofetil",{"EARLY_PHASE1":3607,"PHASE1":3609,"PHASE2":3611,"PHASE3":3613,"PHASE4":3615,"NA":3617},{"trials":3608,"activeCount":8},[],{"trials":3610,"activeCount":8},[],{"trials":3612,"activeCount":8},[],{"trials":3614,"activeCount":8},[],{"trials":3616,"activeCount":8},[],{"trials":3618,"activeCount":8},[3619],{"nctId":3620,"briefTitle":3621,"status":60,"phases":3622,"start":3623,"enrollment":197,"conditions":3624,"interventions":3626},"NCT00007059","Study of the Pharmacokinetics of Mycophenolate Mofetil in Patients Who Have Undergone Orthotopic Liver Transplantation",[41],"1998-06",[3625],"Graft Versus Host Disease",[3605],{"intervention":3628,"totalTrials":45,"cells":3629},"standard gadolinium contrast",{"EARLY_PHASE1":3630,"PHASE1":3632,"PHASE2":3634,"PHASE3":3636,"PHASE4":3638,"NA":3640},{"trials":3631,"activeCount":8},[],{"trials":3633,"activeCount":8},[],{"trials":3635,"activeCount":8},[],{"trials":3637,"activeCount":8},[],{"trials":3639,"activeCount":8},[],{"trials":3641,"activeCount":8},[3642],{"nctId":3643,"briefTitle":3644,"status":167,"phases":3645,"start":3646,"enrollment":3647,"conditions":3648,"interventions":3649},"NCT00006060","Diagnostic Study of Quantitative Imaging and Spectroscopy in Patients With Multiple Sclerosis",[],"1999-04",100,[32],[3628],{"intervention":3651,"totalTrials":45,"cells":3652},"Tacrolimus",{"EARLY_PHASE1":3653,"PHASE1":3655,"PHASE2":3657,"PHASE3":3659,"PHASE4":3661,"NA":3663},{"trials":3654,"activeCount":8},[],{"trials":3656,"activeCount":8},[],{"trials":3658,"activeCount":8},[],{"trials":3660,"activeCount":8},[],{"trials":3662,"activeCount":8},[],{"trials":3664,"activeCount":8},[3665],{"nctId":3666,"briefTitle":3667,"status":60,"phases":3668,"conditions":3669,"interventions":3671},"NCT00028171","Pharmacokinetics of Tacrolimus in Kidney Transplant Recipients: Once Daily Versus Twice Daily Dosing",[41],[3670],"Kidney Transplantation",[3651],{"intervention":3673,"totalTrials":45,"cells":3674},"phosphatidylcholine",{"EARLY_PHASE1":3675,"PHASE1":3677,"PHASE2":3679,"PHASE3":3681,"PHASE4":3683,"NA":3685},{"trials":3676,"activeCount":8},[],{"trials":3678,"activeCount":8},[],{"trials":3680,"activeCount":8},[],{"trials":3682,"activeCount":8},[],{"trials":3684,"activeCount":8},[],{"trials":3686,"activeCount":8},[3687],{"nctId":3688,"briefTitle":3689,"status":60,"phases":3690,"completion":1613,"start":1613,"enrollment":45,"conditions":3691,"interventions":3694},"NCT00006061","Study of Phosphatidylcholine in a Patient With Methionine Adenosyltransferase Deficiency",[41],[3692,3693],"Methionine Adenosyltransferase Deficiency","Metabolism, Inborn Errors",[3673],{"intervention":3696,"totalTrials":45,"cells":3697},"Clopidogrel",{"EARLY_PHASE1":3698,"PHASE1":3700,"PHASE2":3702,"PHASE3":3704,"PHASE4":3706,"NA":3708},{"trials":3699,"activeCount":8},[],{"trials":3701,"activeCount":8},[],{"trials":3703,"activeCount":8},[],{"trials":3705,"activeCount":8},[],{"trials":3707,"activeCount":8},[],{"trials":3709,"activeCount":8},[3710],{"nctId":3711,"briefTitle":3712,"status":167,"phases":3713,"conditions":3714,"interventions":3717},"NCT00004564","The Inhibition of Platelet Antiaggregating Activity of Clopidogrel by Atorvastatin Detected by Erythromycin Breath Test: a Metabolic Inhibition of Hepatic Cytochrome P450-3A",[41],[3715,3716],"Hypercholesterolemia","Thrombosis",[3696,3718],"Atorvastatin",{"intervention":3718,"totalTrials":45,"cells":3720},{"EARLY_PHASE1":3721,"PHASE1":3723,"PHASE2":3725,"PHASE3":3727,"PHASE4":3729,"NA":3731},{"trials":3722,"activeCount":8},[],{"trials":3724,"activeCount":8},[],{"trials":3726,"activeCount":8},[],{"trials":3728,"activeCount":8},[],{"trials":3730,"activeCount":8},[],{"trials":3732,"activeCount":8},[3733],{"nctId":3711,"briefTitle":3712,"status":167,"phases":3734,"conditions":3735,"interventions":3736},[41],[3715,3716],[3696,3718],{"intervention":3738,"totalTrials":45,"cells":3739},"rifabutin",{"EARLY_PHASE1":3740,"PHASE1":3742,"PHASE2":3744,"PHASE3":3746,"PHASE4":3748,"NA":3750},{"trials":3741,"activeCount":8},[],{"trials":3743,"activeCount":8},[],{"trials":3745,"activeCount":8},[],{"trials":3747,"activeCount":8},[],{"trials":3749,"activeCount":8},[],{"trials":3751,"activeCount":8},[3752],{"nctId":3753,"briefTitle":3754,"status":167,"phases":3755,"conditions":3756,"interventions":3757},"NCT00018083","Intensive Pharmacokinetics of the Nelfinavir-Rifabutin Interaction in Patients With HIV-Related Tuberculosis Treated With a Rifabutin-Based Regimen",[41],[1013,20],[3738,3758,3759],"isoniazid","efavirenz",{"intervention":3758,"totalTrials":45,"cells":3761},{"EARLY_PHASE1":3762,"PHASE1":3764,"PHASE2":3766,"PHASE3":3768,"PHASE4":3770,"NA":3772},{"trials":3763,"activeCount":8},[],{"trials":3765,"activeCount":8},[],{"trials":3767,"activeCount":8},[],{"trials":3769,"activeCount":8},[],{"trials":3771,"activeCount":8},[],{"trials":3773,"activeCount":8},[3774],{"nctId":3753,"briefTitle":3754,"status":167,"phases":3775,"conditions":3776,"interventions":3777},[41],[1013,20],[3738,3758,3759],{"intervention":3759,"totalTrials":45,"cells":3779},{"EARLY_PHASE1":3780,"PHASE1":3782,"PHASE2":3784,"PHASE3":3786,"PHASE4":3788,"NA":3790},{"trials":3781,"activeCount":8},[],{"trials":3783,"activeCount":8},[],{"trials":3785,"activeCount":8},[],{"trials":3787,"activeCount":8},[],{"trials":3789,"activeCount":8},[],{"trials":3791,"activeCount":8},[3792],{"nctId":3753,"briefTitle":3754,"status":167,"phases":3793,"conditions":3794,"interventions":3795},[41],[1013,20],[3738,3758,3759],{"intervention":3125,"totalTrials":45,"cells":3797},{"EARLY_PHASE1":3798,"PHASE1":3800,"PHASE2":3802,"PHASE3":3804,"PHASE4":3806,"NA":3808},{"trials":3799,"activeCount":8},[],{"trials":3801,"activeCount":8},[],{"trials":3803,"activeCount":8},[],{"trials":3805,"activeCount":8},[],{"trials":3807,"activeCount":8},[],{"trials":3809,"activeCount":8},[3810],{"nctId":3117,"briefTitle":3118,"status":167,"phases":3811,"start":1090,"enrollment":3120,"conditions":3812,"interventions":3813},[41],[3122,3123],[3125,3126,3127,3091,883,3128,3114,3115,3129,3130],{"intervention":3126,"totalTrials":45,"cells":3815},{"EARLY_PHASE1":3816,"PHASE1":3818,"PHASE2":3820,"PHASE3":3822,"PHASE4":3824,"NA":3826},{"trials":3817,"activeCount":8},[],{"trials":3819,"activeCount":8},[],{"trials":3821,"activeCount":8},[],{"trials":3823,"activeCount":8},[],{"trials":3825,"activeCount":8},[],{"trials":3827,"activeCount":8},[3828],{"nctId":3117,"briefTitle":3118,"status":167,"phases":3829,"start":1090,"enrollment":3120,"conditions":3830,"interventions":3831},[41],[3122,3123],[3125,3126,3127,3091,883,3128,3114,3115,3129,3130],{"intervention":3127,"totalTrials":45,"cells":3833},{"EARLY_PHASE1":3834,"PHASE1":3836,"PHASE2":3838,"PHASE3":3840,"PHASE4":3842,"NA":3844},{"trials":3835,"activeCount":8},[],{"trials":3837,"activeCount":8},[],{"trials":3839,"activeCount":8},[],{"trials":3841,"activeCount":8},[],{"trials":3843,"activeCount":8},[],{"trials":3845,"activeCount":8},[3846],{"nctId":3117,"briefTitle":3118,"status":167,"phases":3847,"start":1090,"enrollment":3120,"conditions":3848,"interventions":3849},[41],[3122,3123],[3125,3126,3127,3091,883,3128,3114,3115,3129,3130],{"intervention":3128,"totalTrials":45,"cells":3851},{"EARLY_PHASE1":3852,"PHASE1":3854,"PHASE2":3856,"PHASE3":3858,"PHASE4":3860,"NA":3862},{"trials":3853,"activeCount":8},[],{"trials":3855,"activeCount":8},[],{"trials":3857,"activeCount":8},[],{"trials":3859,"activeCount":8},[],{"trials":3861,"activeCount":8},[],{"trials":3863,"activeCount":8},[3864],{"nctId":3117,"briefTitle":3118,"status":167,"phases":3865,"start":1090,"enrollment":3120,"conditions":3866,"interventions":3867},[41],[3122,3123],[3125,3126,3127,3091,883,3128,3114,3115,3129,3130],{"intervention":3129,"totalTrials":45,"cells":3869},{"EARLY_PHASE1":3870,"PHASE1":3872,"PHASE2":3874,"PHASE3":3876,"PHASE4":3878,"NA":3880},{"trials":3871,"activeCount":8},[],{"trials":3873,"activeCount":8},[],{"trials":3875,"activeCount":8},[],{"trials":3877,"activeCount":8},[],{"trials":3879,"activeCount":8},[],{"trials":3881,"activeCount":8},[3882],{"nctId":3117,"briefTitle":3118,"status":167,"phases":3883,"start":1090,"enrollment":3120,"conditions":3884,"interventions":3885},[41],[3122,3123],[3125,3126,3127,3091,883,3128,3114,3115,3129,3130],{"intervention":3130,"totalTrials":45,"cells":3887},{"EARLY_PHASE1":3888,"PHASE1":3890,"PHASE2":3892,"PHASE3":3894,"PHASE4":3896,"NA":3898},{"trials":3889,"activeCount":8},[],{"trials":3891,"activeCount":8},[],{"trials":3893,"activeCount":8},[],{"trials":3895,"activeCount":8},[],{"trials":3897,"activeCount":8},[],{"trials":3899,"activeCount":8},[3900],{"nctId":3117,"briefTitle":3118,"status":167,"phases":3901,"start":1090,"enrollment":3120,"conditions":3902,"interventions":3903},[41],[3122,3123],[3125,3126,3127,3091,883,3128,3114,3115,3129,3130],{"intervention":3905,"totalTrials":45,"cells":3906},"fructose",{"EARLY_PHASE1":3907,"PHASE1":3909,"PHASE2":3911,"PHASE3":3913,"PHASE4":3915,"NA":3917},{"trials":3908,"activeCount":8},[],{"trials":3910,"activeCount":8},[],{"trials":3912,"activeCount":8},[],{"trials":3914,"activeCount":8},[],{"trials":3916,"activeCount":8},[],{"trials":3918,"activeCount":8},[3919],{"nctId":3920,"briefTitle":3921,"status":60,"phases":3922,"start":206,"enrollment":197,"conditions":3923,"interventions":3925},"NCT00004797","Pilot Study of Fructose for Sickle Cell Crisis",[41],[3924],"Sickle Cell Anemia",[3905],{"intervention":3927,"totalTrials":45,"cells":3928},"thioctic acid",{"EARLY_PHASE1":3929,"PHASE1":3931,"PHASE2":3933,"PHASE3":3935,"PHASE4":3937,"NA":3939},{"trials":3930,"activeCount":8},[],{"trials":3932,"activeCount":8},[],{"trials":3934,"activeCount":8},[],{"trials":3936,"activeCount":8},[],{"trials":3938,"activeCount":8},[],{"trials":3940,"activeCount":8},[3941],{"nctId":3942,"briefTitle":3943,"status":60,"phases":3944,"start":3945,"enrollment":45,"conditions":3946,"interventions":3948},"NCT00004770","Pilot Compassionate Use Study of Thioctic Acid Treatment in Mitochondrial Myopathy",[41],"1995-10",[3947],"Mitochondrial Myopathy",[3927],{"intervention":3950,"totalTrials":45,"cells":3951},"Digoxin",{"EARLY_PHASE1":3952,"PHASE1":3954,"PHASE2":3956,"PHASE3":3958,"PHASE4":3960,"NA":3962},{"trials":3953,"activeCount":8},[],{"trials":3955,"activeCount":8},[],{"trials":3957,"activeCount":8},[],{"trials":3959,"activeCount":8},[],{"trials":3961,"activeCount":8},[],{"trials":3963,"activeCount":8},[3964],{"nctId":3965,"briefTitle":3966,"status":60,"phases":3967,"conditions":3968,"interventions":3969},"NCT00006330","Pharmacokinetic and Pharmacodynamic Interaction Study of Digoxin and Hawthorn",[41],[2628],[3950,3970],"Hawthorn",{"intervention":3970,"totalTrials":45,"cells":3972},{"EARLY_PHASE1":3973,"PHASE1":3975,"PHASE2":3977,"PHASE3":3979,"PHASE4":3981,"NA":3983},{"trials":3974,"activeCount":8},[],{"trials":3976,"activeCount":8},[],{"trials":3978,"activeCount":8},[],{"trials":3980,"activeCount":8},[],{"trials":3982,"activeCount":8},[],{"trials":3984,"activeCount":8},[3985],{"nctId":3965,"briefTitle":3966,"status":60,"phases":3986,"conditions":3987,"interventions":3988},[41],[2628],[3950,3970],{"intervention":3990,"totalTrials":45,"cells":3991},"calcium gluconate",{"EARLY_PHASE1":3992,"PHASE1":3994,"PHASE2":3996,"PHASE3":3998,"PHASE4":4000,"NA":4002},{"trials":3993,"activeCount":8},[],{"trials":3995,"activeCount":8},[],{"trials":3997,"activeCount":8},[],{"trials":3999,"activeCount":8},[],{"trials":4001,"activeCount":8},[],{"trials":4003,"activeCount":8},[4004],{"nctId":4005,"briefTitle":4006,"status":60,"phases":4007,"start":1276,"enrollment":4008,"conditions":4009,"interventions":4016},"NCT00004361","Study of the Relationship Between Calcium Levels and Intact Parathyroid Hormone (iPTH) in Adults With Repaired or Palliated Conotruncal Cardiac Defects",[],150,[4010,4011,4012,4013,4014,4015],"Hypoparathyroidism","Tetralogy of Fallot","Pulmonary Valve Stenosis","Conotruncal Cardiac Defects","Heart Defects, Congenital","Pulmonary Atresia",[3990,4017],"sodium citrate",{"intervention":4017,"totalTrials":45,"cells":4019},{"EARLY_PHASE1":4020,"PHASE1":4022,"PHASE2":4024,"PHASE3":4026,"PHASE4":4028,"NA":4030},{"trials":4021,"activeCount":8},[],{"trials":4023,"activeCount":8},[],{"trials":4025,"activeCount":8},[],{"trials":4027,"activeCount":8},[],{"trials":4029,"activeCount":8},[],{"trials":4031,"activeCount":8},[4032],{"nctId":4005,"briefTitle":4006,"status":60,"phases":4033,"start":1276,"enrollment":4008,"conditions":4034,"interventions":4035},[],[4010,4011,4012,4013,4014,4015],[3990,4017],{"intervention":4037,"totalTrials":45,"cells":4038},"calcium acetate",{"EARLY_PHASE1":4039,"PHASE1":4041,"PHASE2":4043,"PHASE3":4045,"PHASE4":4047,"NA":4049},{"trials":4040,"activeCount":8},[],{"trials":4042,"activeCount":8},[],{"trials":4044,"activeCount":8},[],{"trials":4046,"activeCount":8},[],{"trials":4048,"activeCount":8},[],{"trials":4050,"activeCount":8},[4051],{"nctId":4052,"briefTitle":4053,"status":60,"phases":4054,"conditions":4055,"interventions":4057},"NCT00018135","Parathyroid Hormone Levels in Relation to the Phosphorus Content of Meals",[41],[4056],"Renal Failure",[4037,4058,4059],"aluminum hydroxide","Sevelamer",{"intervention":4058,"totalTrials":45,"cells":4061},{"EARLY_PHASE1":4062,"PHASE1":4064,"PHASE2":4066,"PHASE3":4068,"PHASE4":4070,"NA":4072},{"trials":4063,"activeCount":8},[],{"trials":4065,"activeCount":8},[],{"trials":4067,"activeCount":8},[],{"trials":4069,"activeCount":8},[],{"trials":4071,"activeCount":8},[],{"trials":4073,"activeCount":8},[4074],{"nctId":4052,"briefTitle":4053,"status":60,"phases":4075,"conditions":4076,"interventions":4077},[41],[4056],[4037,4058,4059],{"intervention":4059,"totalTrials":45,"cells":4079},{"EARLY_PHASE1":4080,"PHASE1":4082,"PHASE2":4084,"PHASE3":4086,"PHASE4":4088,"NA":4090},{"trials":4081,"activeCount":8},[],{"trials":4083,"activeCount":8},[],{"trials":4085,"activeCount":8},[],{"trials":4087,"activeCount":8},[],{"trials":4089,"activeCount":8},[],{"trials":4091,"activeCount":8},[4092],{"nctId":4052,"briefTitle":4053,"status":60,"phases":4093,"conditions":4094,"interventions":4095},[41],[4056],[4037,4058,4059],{"intervention":4097,"totalTrials":45,"cells":4098},"estradiol",{"EARLY_PHASE1":4099,"PHASE1":4101,"PHASE2":4103,"PHASE3":4105,"PHASE4":4107,"NA":4109},{"trials":4100,"activeCount":8},[],{"trials":4102,"activeCount":8},[],{"trials":4104,"activeCount":8},[],{"trials":4106,"activeCount":8},[],{"trials":4108,"activeCount":8},[],{"trials":4110,"activeCount":8},[4111],{"nctId":4112,"briefTitle":4113,"status":60,"phases":4114,"start":711,"enrollment":4115,"conditions":4116,"interventions":4117},"NCT00006133","Randomized Study of Oral Contraceptives or Hormone Replacement Therapy in Women With Systemic Lupus Erythematosus",[41],970,[17],[4097,4118,4119,4120],"ethinyl estradiol","medroxyprogesterone","norethindrone",{"intervention":4118,"totalTrials":45,"cells":4122},{"EARLY_PHASE1":4123,"PHASE1":4125,"PHASE2":4127,"PHASE3":4129,"PHASE4":4131,"NA":4133},{"trials":4124,"activeCount":8},[],{"trials":4126,"activeCount":8},[],{"trials":4128,"activeCount":8},[],{"trials":4130,"activeCount":8},[],{"trials":4132,"activeCount":8},[],{"trials":4134,"activeCount":8},[4135],{"nctId":4112,"briefTitle":4113,"status":60,"phases":4136,"start":711,"enrollment":4115,"conditions":4137,"interventions":4138},[41],[17],[4097,4118,4119,4120],{"intervention":4119,"totalTrials":45,"cells":4140},{"EARLY_PHASE1":4141,"PHASE1":4143,"PHASE2":4145,"PHASE3":4147,"PHASE4":4149,"NA":4151},{"trials":4142,"activeCount":8},[],{"trials":4144,"activeCount":8},[],{"trials":4146,"activeCount":8},[],{"trials":4148,"activeCount":8},[],{"trials":4150,"activeCount":8},[],{"trials":4152,"activeCount":8},[4153],{"nctId":4112,"briefTitle":4113,"status":60,"phases":4154,"start":711,"enrollment":4115,"conditions":4155,"interventions":4156},[41],[17],[4097,4118,4119,4120],{"intervention":4120,"totalTrials":45,"cells":4158},{"EARLY_PHASE1":4159,"PHASE1":4161,"PHASE2":4163,"PHASE3":4165,"PHASE4":4167,"NA":4169},{"trials":4160,"activeCount":8},[],{"trials":4162,"activeCount":8},[],{"trials":4164,"activeCount":8},[],{"trials":4166,"activeCount":8},[],{"trials":4168,"activeCount":8},[],{"trials":4170,"activeCount":8},[4171],{"nctId":4112,"briefTitle":4113,"status":60,"phases":4172,"start":711,"enrollment":4115,"conditions":4173,"interventions":4174},[41],[17],[4097,4118,4119,4120],{"intervention":4176,"totalTrials":45,"cells":4177},"cosyntropin",{"EARLY_PHASE1":4178,"PHASE1":4180,"PHASE2":4182,"PHASE3":4184,"PHASE4":4186,"NA":4188},{"trials":4179,"activeCount":8},[],{"trials":4181,"activeCount":8},[],{"trials":4183,"activeCount":8},[],{"trials":4185,"activeCount":8},[],{"trials":4187,"activeCount":8},[],{"trials":4189,"activeCount":8},[4190],{"nctId":4191,"briefTitle":4192,"status":167,"phases":4193,"start":4194,"enrollment":941,"conditions":4195,"interventions":4198},"NCT00006270","Study of the Approximate Entropy of Adrenocorticotropic Hormone and Cortisol Secretion in Patients With Head Injury",[],"1998-02",[4196,4197],"Brain Injury","Craniocerebral Trauma",[4176,4199],"metyrapone",{"intervention":4199,"totalTrials":45,"cells":4201},{"EARLY_PHASE1":4202,"PHASE1":4204,"PHASE2":4206,"PHASE3":4208,"PHASE4":4210,"NA":4212},{"trials":4203,"activeCount":8},[],{"trials":4205,"activeCount":8},[],{"trials":4207,"activeCount":8},[],{"trials":4209,"activeCount":8},[],{"trials":4211,"activeCount":8},[],{"trials":4213,"activeCount":8},[4214],{"nctId":4191,"briefTitle":4192,"status":167,"phases":4215,"start":4194,"enrollment":941,"conditions":4216,"interventions":4217},[],[4196,4197],[4176,4199]]